

0001

1 WEDNESDAY, JANUARY 27, 1999 MORNING SESSION
2 *****
3 THE COURT: OKAY. MR. OHLEMEYER, YOU MAY CALL
4 YOUR FIRST WITNESS.
5 MR. OHLEMEYER: VERY GOOD, YOUR HONOR. DR.
6 GEORGE HENSLEY, H-E-N-S-L-E-Y.
7 TESTIMONY OF
8 GEORGE HENSLEY, M.D.
9 A WITNESS CALLED ON BEHALF OF THE DEFENDANT, HAVING BEEN
10 DULY SWORN, TESTIFIED AS FOLLOWS:
11 THE CLERK: PLEASE STATE YOUR NAME.
12 THE WITNESS: GEORGE HENSLEY.
13 THE CLERK: PLEASE SPELL YOUR NAME.
14 THE WITNESS: H-E-N-S-L-E-Y.
15 THE CLERK: IS GEORGE G-E-O-R-G-E?
16 THE WITNESS: G-E-O-R-G-E.
17 THE CLERK: THANK YOU. PLEASE TAKE THE STAND.
18

19 DIRECT EXAMINATION
20 BY MR. OHLEMEYER: Q. GOOD MORNING, DOCTOR.
21 A. GOOD MORNING.
22 Q. YOU ARE A PATHOLOGIST; IS THAT CORRECT?
23 A. YES, SIR.
24 Q. HOW LONG HAVE YOU BEEN A PATHOLOGIST?
25 A. WELL, I WAS ENGAGED IN THE ACTIVE PRACTICE OF
26 PATHOLOGY FOR SOMETHING OVER 30 YEARS. I WAS
27 BOARD-CERTIFIED IN THE 1960S.
28 Q. AND WHERE DO YOU CURRENTLY PRACTICE PATHOLOGY?
JUDITH ANN OSSA, CSR NO. 2310

0002

1 A. I'M RETIRED. I RETIRED IN 1995 FROM THE
2 UNIVERSITY OF MIAMI SCHOOL OF MEDICINE.
3 Q. AND WHAT WERE YOU DOING AT THE UNIVERSITY OF
4 MIAMI SCHOOL OF MEDICINE AT THE TIME YOU RETIRED?
5 A. WELL, I WAS A PROFESSOR IN THE DEPARTMENT, AND I
6 HAD THREE GENERAL KINDS OF DUTIES. FIRST, PROVIDING
7 DIAGNOSTIC SERVICES TO PATIENTS HOSPITALIZED AT THE TEACHING
8 HOSPITAL. SECONDLY, TEACHING POSTGRADUATE STUDENTS IN
9 PATHOLOGY. AND THIRDLY, CONDUCTING RESEARCH.
10 Q. CAN YOU TELL US WHAT DIAGNOSTIC SERVICES ARE?
11 A. WELL, THERE ARE TWO TYPES. THE FIRST TYPE IS
12 SURGICAL PATHOLOGY, WHERE YOU RECEIVE BIOPSIES OR ORGANS
13 REMOVED FROM PATIENTS WHO ARE ALIVE AND MAKE A DIAGNOSIS OF
14 THE DISEASE.
15 THE SECOND CATEGORY WOULD BE THE AUTOPSY SERVICE,
16 WHERE YOU INVESTIGATE THE DISEASES OF PATIENTS WHO HAVE
17 DIED, MANY OF WHOM YOU SAW IN THE FIRST PHASE OF STUDY,
18 NAMELY, THE EVALUATION OF BIOPSIES.
19 Q. AND WHEN YOU SAID YOU WERE INVOLVED WITH TEACHING
20 POSTGRADUATE STUDENTS, ARE THOSE MEDICAL DOCTOR STUDENTS?
21 A. YES, FOR THE MOST PART, ALTHOUGH I WAS INVOLVED
22 IN TEACHING PH.D. CANDIDATES AT THE ROSENSTIEL INSTITUTE FOR
23 MARINE AND ATMOSPHERIC SCIENCE.
24 Q. AND YOU SAID YOU WERE CONDUCTING RESEARCH.
25 WHAT TYPE OF RESEARCH DID YOU CONDUCT?
26 A. WELL, OVER THE YEARS, I WORKED IN A NUMBER OF
27 FIELDS. IN WISCONSIN, I DID A SUBSTANTIAL AMOUNT OF WORK ON
28 LUNG DISEASE, SPECIFICALLY, HYPERSENSITIVITY, DISEASES OF
JUDITH ANN OSSA, CSR NO. 2310

0003

1 THE LUNG. THESE ARE DISEASES CAUSED BY ALLERGIC MECHANISMS
2 OF INJURY.

3 THROUGHOUT THE YEARS, I'VE WORKED IN THE AREA OF
4 GASTROINTESTINAL TRACT PATHOLOGY. AND IN THE LAST 10 YEARS,
5 I, LIKE MANY OTHER ACADEMIC PATHOLOGISTS, HAD TO SPEND A
6 GOOD DEAL OF TIME WITH THE INVESTIGATION OF AIDS/HIV
7 INFECTION.

8 Q. CAN YOU DESCRIBE FOR US YOUR EDUCATION, YOUR
9 FORMAL EDUCATION THAT LED UP TO YOUR MEDICAL DEGREE.

10 A. WELL, I WENT TO UNDERGRADUATE SCHOOL AT
11 NORTHWESTERN OHIO, A CITY CALLED TOLEDO. I GRADUATED WITH A
12 BACHELOR OF SCIENCE DEGREE IN ZOOLOGY AND CHEMISTRY.

13 I THEN WENT TO THE OHIO STATE UNIVERSITY WHERE I
14 GOT MY M.D. DEGREE AFTER FOUR YEARS.

15 Q. AND WHEN WAS THAT?

16 A. I THINK IT WAS ABOUT 1957, '58. YOU'LL DISCOVER
17 MY MEMORY FOR DATES IS NOT VERY GOOD.

18 BUT AFTER GRADUATING FROM MEDICAL SCHOOL, I TOOK
19 A GENERAL ROTATING INTERNSHIP WITH AN EMPHASIS ON SURGERY,
20 MEDICINE AND SOME OBSTETRICS. THAT WAS A CLINICAL YEAR.

21 Q. CAN I INTERRUPT YOU FOR A MINUTE.

22 A. YES, SIR.

23 Q. CAN YOU TELL US WHAT YOU MEAN BY A "CLINICAL
24 YEAR" IN AN INTERNSHIP.

25 A. WELL, DURING THAT YEAR, I WAS SEEING PATIENTS
26 WITH A WIDE VARIETY OF DISEASES AND INJURIES. I
27 PARTICIPATED IN THE DIAGNOSIS AND TREATMENT OF PATIENTS OF
28 PRIVATE PRACTITIONERS OF MEDICINE.

JUDITH ANN OSSA, CSR NO. 2310

0004

1 BUT IN ADDITION, OF COURSE, I WORKED IN THE
2 MEDICAL CLINICS, WHERE I WAS RESPONSIBLE FOR SEEING PATIENTS
3 AND WORKING THEM UP DIAGNOSTICALLY.

4 Q. AND THEN, DID YOU PROCEED TO A RESIDENCY?

5 A. I DID. AND FOR THAT CLINICAL YEAR, I WENT TO THE
6 UNIVERSITY OF CINCINNATI SCHOOL OF MEDICINE. THAT'S
7 SITUATED IN SOUTHERN OHIO. I SPENT A YEAR THERE STUDYING
8 ANATOMIC PATHOLOGY.

9 AND THEN I RETURNED TO THE HOSPITAL, WHERE I TOOK
10 MY INTERNSHIP IN TOLEDO, AND I TOOK THREE ADDITIONAL YEARS
11 IN TRAINING IN PATHOLOGY, WHICH INVOLVED BOTH ANATOMICAL
12 PATHOLOGY AND CLINICAL PATHOLOGY.

13 I REALLY EMPHASIZED ON ANATOMICAL PATHOLOGY
14 THROUGHOUT THOSE FOUR YEARS OF TRAINING.

15 Q. WE HAVE HEARD A LITTLE BIT ABOUT PATHOLOGY
16 ALREADY.

17 CAN YOU TELL US BRIEFLY WHAT ANATOMIC PATHOLOGY
18 INVOLVES.

19 A. WELL, AN ANATOMIC PATHOLOGIST IS A PERSON WHO
20 PRACTICES MEDICINE BY WORKING WITH OTHER PHYSICIANS TO HELP
21 THEM MAKE DIAGNOSES AND PLAN TREATMENT.

22 THE THING THAT DISTINGUISHES THOSE OF US WHO WORK
23 IN ANATOMIC PATHOLOGY IS THAT WE HOLD THINGS IN OUR HANDS
24 AND LOOK AT THEM, AND WE USE THE MICROSCOPE A LOT, OF
25 COURSE.

26 BASICALLY, WE DO WHAT I'VE ALREADY DESCRIBED,
27 LOOK AT BIOPSIES OR ORGANS OR DO AUTOPSIES. THAT'S THE
28 GENERAL DESCRIPTION.

JUDITH ANN OSSA, CSR NO. 2310

0005

1 Q. DID YOU THEN OBTAIN A BOARD CERTIFICATION IN
2 ANATOMIC PATHOLOGY?

3 A. I DID.

4 Q. AND WE'VE HEARD A LITTLE ABOUT THAT ALREADY.

5 TELL US BRIEFLY WHAT IS INVOLVED IN OBTAINING THE

6 BOARD CERTIFICATION.

7 A. WELL, THE BOARD CERTIFICATION, WHICH,
8 INCIDENTALLY, WAS BASED ON AN EXAMINATION TAKEN HERE IN SAN
9 FRANCISCO, ENTAILED TAKING A COMPREHENSIVE WRITTEN
10 EXAMINATION, AND ALSO LOOKING AT A LARGE NUMBER OF ORGANS
11 THAT WERE BROUGHT TO THE TESTING SITE BY EXPERTS IN THEIR
12 FIELDS, AND EXAMINING THEM AND GIVING OPINIONS.

13 AND THEN, ALSO LOOKING AT MICROSCOPIC SLIDES IN
14 THE SAME WAY.

15 Q. THROUGHOUT YOUR CAREER -- BY THE WAY, DOCTOR,
16 WHEN DID YOU OBTAIN YOUR BOARD CERTIFICATION?

17 A. I THINK IT'S '63. IT COULD HAVE BEEN A LITTLE
18 LATER. I'M NOT SURE.

19 Q. IF YOUR RESUME SAYS '63, THAT WOULD BE CONSISTENT
20 WITH YOUR RECOLLECTION --

21 A. YES.

22 Q. -- THROUGHOUT?

23 A. I DON'T HAVE IT BEFORE ME.

24 Q. THROUGHOUT YOUR CAREER, HAVE YOU BEEN INVOLVED IN
25 TEACHING DOCTORS AND OTHER MEDICAL STUDENTS?

26 A. YES. IN WISCONSIN, IN THE EARLY DAYS, I TAUGHT A
27 LOT OF UNDERGRADUATE STUDENTS. THEY WERE STUDENTS USUALLY
28 AT THE SENIOR LEVEL IN MEDICAL SCHOOL.

JUDITH ANN OSSA, CSR NO. 2310

0006

1 BUT THEN, I ALSO TAUGHT PHYSICIANS WHO HAD
2 COMPLETED MEDICAL SCHOOL AND WERE STUDYING PATHOLOGY BECAUSE
3 THEY WISHED TO BECOME PATHOLOGISTS THEMSELVES. I CONTINUED
4 THAT SECOND ACTIVITY IN FLORIDA THE LAST 20 YEARS.

5 IN ADDITION, I TAUGHT A VARIETY OF POSTGRADUATE
6 COURSES FOR PHYSICIANS WHO WERE IN INTERNAL MEDICINE SURGERY
7 AND PATHOLOGY.

8 AND AS I MENTIONED BEFORE, I WAS ON THE FACULTY
9 OF THE ROSENSTIEL INSTITUTE, ADVISING PH.D. CANDIDATES ON
10 THEIR THESIS.

11 Q. HAVE YOU DONE WHAT THEY CALL VISITING
12 PROFESSORSHIPS?

13 A. YES, TWICE.

14 Q. TELL US WHAT THAT INVOLVES.

15 A. WELL, IN THE EARLY 1980S, I THINK IT WAS ABOUT
16 1982, I WENT TO HAITI, TO THE MEDICAL SCHOOL AT PORT AU
17 PRINCE. THE REASON FOR MY VISIT WAS THAT THERE WAS REASON
18 TO SUSPECT THAT HIV INFECTION WAS PRESENT ON THE ISLANDS,
19 BUT IT HAD NEVER BEEN PROVEN.

20 THE FACULTY THERE LACKED SOME OF THE SKILLS AND
21 RESOURCES THAT WE HAD IN MIAMI, SO I WENT DOWN TO HELP THEM
22 TO DEVELOP THEIR RESOURCES AND SKILLS AND LOOK FOR THE
23 INFECTION.

24 AND SURE ENOUGH, WE DID FIND A SIGNIFICANT NUMBER
25 OF PATIENTS AT THE UNIVERSITY HOSPITAL WHO DID HAVE HIV
26 INFECTION AND WHO HAD AIDS.

27 AROUND THE SAME TIME, I WENT TO MEXICO CITY FOR
28 WHAT TURNED OUT TO BE AN ABBREVIATED TRIP, ONLY ABOUT SIX
JUDITH ANN OSSA, CSR NO. 2310

0007

1 WEEKS, WHERE I WAS A VISITING PROFESSOR. THE FACULTY OF THE
2 AUTONOMOUS UNIVERSITY.

3 I WAS INVITED THERE BY THE CHAIRMAN, DR. ALBERTO
4 SAAVEDRA, S-A-V-A-A-D-R-A, TO PARTICIPATE IN TEACHING HIS
5 STUDENTS, AND ALSO TO LOOK AT THE QUESTION OF AIDS IN
6 MEXICO.

7 WHILE THERE, WE DID FIND THE FIRST CASE IN
8 MEXICO.

9 Q. THROUGHOUT THE YEARS, HAVE YOU HAD ADMINISTRATIVE
10 RESPONSIBILITIES AT THE UNIVERSITY?

11 A. FROM TIME TO TIME, YES, I HAVE SERVED AS DIRECTOR
12 OF THE AUTOPSY SERVICE.

13 I'VE ALSO SERVED AS DIRECTOR OF ANATOMICAL
14 PATHOLOGY, WHICH INCLUDES THE SURGICAL PATHOLOGY AREA,
15 AUTOPSY AND CYTOLOGY.

16 I'VE HELD OTHER ADMINISTRATIVE POSITIONS IN THE
17 DEPARTMENT FROM TIME TO TIME, BUT I TRIED TO AVOID AS MUCH
18 AS POSSIBLE ADMINISTRATIVE RESPONSIBILITIES.

19 Q. IT LEAVES MORE TIME --

20 A. FOR WORK.

21 Q. YOU MENTIONED THAT YOU CONDUCTED RESEARCH OVER
22 THE YEARS.

23 HAVE YOU PUBLISHED THE RESULTS OF THAT RESEARCH
24 IN MEDICAL AND SCIENTIFIC JOURNALS?

25 A. YES.

26 Q. WHAT SORTS OF JOURNALS HAVE YOU PUBLISHED YOUR
27 RESEARCH IN?

28 A. WELL, REALLY, THEY ARE QUITE DIVERSE. I HAVE
JUDITH ANN OSSA, CSR NO. 2310

0008

1 PUBLISHED, OF COURSE, IN THE PATHOLOGY JOURNALS, THE
2 STANDARD ONES.

3 BUT IN ADDITION, THERE ARE TITLES IN THE JOURNAL
4 OF THE AMERICAN MEDICAL ASSOCIATION, GASTROENTEROLOGY AND
5 OTHER CLINICAL JOURNALS, BECAUSE A LOT OF MY WORK HAS TO DO
6 WITH WORKING JOINTLY AND COOPERATIVELY WITH PHYSICIANS IN
7 OTHER SPECIALTIES.

8 Q. DOCTOR, IN TERMS OF YOUR BACKGROUND, YOUR
9 EDUCATION, HOW DO YOU APPLY THAT TO THE STUDY OF DISEASE BY
10 PATHOLOGICAL METHODS?

11 A. WELL, I THINK AN ANATOMIC PATHOLOGIST IS A PERSON
12 WHO SHOULD HAVE AN OPEN MIND WHEN A DIAGNOSTIC PROBLEM IS
13 BROUGHT TO HIM, AND HE SHOULD HAVE AN INDEPENDENT VIEWPOINT
14 BASED ON ANATOMY AND THE PRINCIPLES OF DISEASE PROCESSES AS
15 THEY RELATE TO ALTERED OR ABNORMAL ANATOMY.

16 SO WHAT WE DO IS INDEPENDENTLY LOOK AT THE
17 PROBLEM AND USE OUR TOOLS -- THE MICROSCOPE, OUR HANDS AND
18 OUR EYES -- IN ARRIVING AT A PATHOLOGICAL DIAGNOSIS, THE
19 DIAGNOSIS WE HOPE IS HELPFUL TO THE CLINICIAN. AND IN MOST
20 CASES, IT IS.

21 Q. AND WHEN YOU SAY "HELPFUL TO THE CLINICIAN," YOU
22 MEAN IN TREATING AND MANAGING THE CARE OF THE PATIENT?

23 A. AND IN ESTABLISHING THE ACTUAL DIAGNOSIS AS WELL,
24 YES.

25 Q. HAVE YOU BEEN INVOLVED IN DIAGNOSING CANCER?

26 A. OH, YES.

27 Q. HAVE YOU BEEN INVOLVED IN THE DIAGNOSIS OF
28 CANCERS THAT START IN THE LUNG?

JUDITH ANN OSSA, CSR NO. 2310

0009

1 A. YES.

2 Q. HAVE YOU BEEN INVOLVED IN -- DO YOU HAVE ANY
3 EXPERIENCE WITH RESPECT TO AUTOPSIES?

4 A. YES. ACTUALLY, I HAVE HAD A CONTINUING
5 INVOLVEMENT IN AUTOPSIES OF HUMAN BEINGS.

6 Q. DOCTOR, YOU MENTIONED -- I THINK WE'VE ALSO HEARD
7 "PATHOLOGICAL DIAGNOSIS."

8 WITH RESPECT TO CANCER, CAN YOU DESCRIBE FOR US
9 HOW A PATHOLOGIST IS ABLE TO DIAGNOSE CANCER IN A PATIENT.

10 A. WELL, WE'RE TALKING ABOUT A LIVING PATIENT, I
11 PRESUME?

12 Q. CORRECT.
13 A. AND LET'S SAY A PATIENT IS SUSPECTED TO HAVE
14 CANCER. WE, OF COURSE, RECOMMEND TO THE SURGEON THAT TO
15 MAKE THE DIAGNOSIS, THEY GO LOOKING WHERE THE TUMOR IS
16 SUSPECTED TO BE, AND THEN TO PROCURE A TISSUE SAMPLE THAT WE
17 CAN PREPARE FOR EXAMINATION UNDER THE MICROSCOPE.
18 Q. ARE THERE OTHER TOOLS YOU CAN USE BESIDES AN
19 ACTUAL TISSUE SAMPLE TO HELP DIAGNOSE CANCER?
20 A. WELL, IN THOSE CASES WHERE BIOPSY IS DIFFICULT OR
21 IMPOSSIBLE, YOU MAY HAVE TO RELY ON EXFOLIATED CYTOLOGY;
22 THAT IS TO SAY, THE EXAMINATION OF CELLS SHED FROM THE
23 SURFACE OF THE SUSPECTED TUMOR.
24 THE PROBLEM WITH THAT IS THAT IT CANNOT TELL YOU
25 WITH CONFIDENCE THE SITE OF ORIGIN OF THE TUMOR IN MOST
26 CASES, AND OCCASIONALLY, IT DOESN'T EVEN TELL YOU CELL
27 TYPE. SO THERE ARE SOME LIMITATIONS ON CYTOLOGY.
28 Q. IS SPUTUM ANALYSIS, SPUTUM CYTOLOGY AN EXAMPLE OF

JUDITH ANN OSSA, CSR NO. 2310

0010

1 THAT?
2 A. YES. IT HAS VERY LIMITED APPLICATION TO THE
3 DIAGNOSIS OF CANCER OF THE LUNG, HOWEVER.
4 Q. AND WHY IS THAT?
5 A. WELL, ONLY ABOUT HALF OR A LITTLE LESS THAN HALF
6 OF CANCERS ORIGINATING WITHIN THE LUNG ARE SITUATED
7 CENTRALLY, WHERE THEY SHED CELLS THAT WE CAN PICK UP BY
8 CYTOLOGIC EXAMINATION.
9 THE OTHERS, WHICH MAY BE A SLIGHT MAJORITY, IF
10 NOT ABOUT HALF, ARE SO FAR OUT IN THE LUNG PARENCHYMA THAT
11 ANY SHED CELLS DON'T SEEM TO GET INTO THE BRONCHIAL TREE AND
12 COME OUT WHERE WE CAN FIND THEM.
13 Q. IN CASES IN WHICH A SMALL CELL CARCINOMA IS FOUND
14 TO BE GROWING OR TO HAVE STARTED IN THE LUNG, WHAT ROLE OR
15 WHAT USE CAN YOU MAKE OF SPUTUM CYTOLOGY IN THE DIAGNOSIS OF
16 THAT DISEASE?
17 A. WELL, I WOULD SAY THAT SPUTUM CYTOLOGY IS NOT A
18 RELIABLE TOOL. I WOULDN'T DEPEND UPON IT.
19 Q. YOU'D WANT MORE INFORMATION TO DIAGNOSE THE
20 DISEASE?
21 A. WELL, IF I WANTED TO RELY ON CYTOLOGY IN SUCH A
22 PATIENT, WHICH I WOULD RECOMMEND DOING -- WHAT I WOULD
23 RECOMMEND DOING IS TO DO A BRONCHOSCOPY, AND THEN TO GET THE
24 CELLS DIRECTLY FROM THE SURFACE OF THE BRONCHUS IN
25 QUESTION. AND PERHAPS TO DO WHAT WE CALL BRONCHIAL WASHINGS
26 AND BRUSHINGS, TO MAKE SURE THAT WE OPTIMIZE THE PROBABILITY
27 OF FINDING DIAGNOSTIC CELLS.
28 THE ADVANTAGE OF THAT IS, I CAN TELL YOU WHERE

JUDITH ANN OSSA, CSR NO. 2310

0011

1 THE TUMOR IS, WHEREAS IF YOU GET MALIGNANT CELLS IN THE
2 SPUTUM CYTOLOGY, THERE IS NO CORRELATION WITH THE SITE
3 INVOLVED.
4 Q. HOW OFTEN IS SPUTUM CYTOLOGY POSITIVE IN CASES IN
5 WHICH A SMALL CELL CARCINOMA IS ULTIMATELY FOUND TO BEGIN OR
6 HAVE BEGUN GROWING IN THE LUNG?
7 A. WELL, IF I UNDERSTAND YOUR QUESTION -- MAY I
8 PARAPHRASE IT?
9 Q. CERTAINLY.
10 A. IF THE QUESTION IS: HOW OFTEN CAN YOU FIND
11 MALIGNANT CELLS BY CYTOLOGIC EXAMINATION IN A PERSON
12 SUSPECTED TO HAVE BRONCHOGENIC CARCINOMA, I WOULD SAY THE
13 ANSWER IS THAT IF YOU USE THE TECHNIQUE OF BRONCHOSCOPY WITH
14 BRONCHIAL BRUSHINGS AND WASHINGS, WHICH I MENTIONED BEFORE,

15 THERE'S A HIGH PROBABILITY THAT YOU WILL FIND THE MALIGNANT
16 CELLS, VERY HIGH.

17 I WOULDN'T WANT TO QUOTE A NUMBER OFF THE TOP OF
18 MY HEAD, BUT YOU WOULD NEED TO USE THAT METHOD. AND IT'S A
19 FAIRLY COMMON METHOD, A STANDARD APPROACH.

20 Q. CAN CANCER BE A DIFFICULT DISEASE TO DIAGNOSE?

21 A. IT CAN BE EXCEPTIONALLY CHALLENGING, YES.

22 Q. AND CAN DETERMINING WHERE IN THE BODY A
23 PARTICULAR CANCER BEGAN GROWING BE A DIFFICULT PROCESS?

24 A. INDEED, IT CAN. IF YOU LOOK AT THE QUESTION FROM
25 THE STANDPOINT OF TUMORS THAT ARE DISCOVERED IN THE LUNG,
26 FOR EXAMPLE, STUDIES HAVE SHOWN THAT SOMEWHERE AROUND 15 TO
27 20 PERCENT OF THE TUMORS FIRST PRESENTING IN THE LUNG HAVE
28 STARTED OUT ELSEWHERE IN THE BODY, AND IT MIGHT BE VERY

JUDITH ANN OSSA, CSR NO. 2310

0012

1 DIFFICULT TO ESTABLISH THAT WITHOUT A THOROUGH CLINICAL
2 WORKUP.

3 AND SOMETIMES, I REGRET TO SAY, EVEN AUTOPSY MAY
4 BE NECESSARY TO DISCOVER THE SITE.

5 Q. HOW OFTEN DOES AN AUTOPSY -- IN YOUR EXPERIENCE,
6 HOW OFTEN DOES AN AUTOPSY PROVIDE INFORMATION TO THE DOCTORS
7 ABOUT THE PLACE WHERE THE CANCER MIGHT HAVE STARTED GROWING
8 THAT IS UNAVAILABLE OR UNKNOWN TO THEM DURING LIFE?

9 A. USUALLY, WE CAN ANSWER THE QUESTION. IT'S ONLY A
10 VERY TINY FRACTION OF CASES THAT AT AUTOPSY WE FAIL TO
11 ESTABLISH WHERE THE PRIMARY SITE IS THAT IS NEWS TO THE
12 PERSON TREATING THE PATIENT.

13 IN A SUBSTANTIAL NUMBER OF CASES -- IN FACT, MOST
14 STUDIES HAVE SHOWN THAT AROUND 40 PERCENT OF THE TIME, A
15 LITTLE LESS, A LITTLE MORE, DEPENDING ON THE STUDY, THE
16 DOCTOR TAKING CARE OF THE PATIENT DURING LIFE EITHER DIDN'T
17 KNOW THE PATIENT HAD CANCER AT ALL OR HE KNEW THE PATIENT
18 HAD CANCER BUT HE DIDN'T KNOW WHAT CANCER IT WAS.

19 Q. WHAT IS IT ABOUT CANCER THAT MAKES IT EITHER
20 DIFFICULT TO DIAGNOSE IN THE FIRST INSTANCE OR DIFFICULT TO
21 DETERMINE THE POINT IN THE BODY WHERE IT ORIGINATED?

22 A. WELL, FOR ONE THING, IT SPREADS. AND OFTEN, YOU
23 KNOW, THE SYMPTOMS OF CANCER ARE NOT APPARENT AT THE SITE
24 WHERE THEY ORIGINATE.

25 FOR EXAMPLE, IN THE PANCREAS, IT'S VERY TYPICAL
26 TO HAVE THE PATIENT SUFFER SIGNS AND SYMPTOMS REFERRING TO
27 OTHER AREAS OF THE BODY THAN THE PANCREAS. AND FREQUENTLY,
28 IT'S NOT UNTIL AUTOPSY THAT YOU CAN FIND TUMORS ORIGINATING

JUDITH ANN OSSA, CSR NO. 2310

0013

1 THERE.

2 SECONDLY -- OR TO ANSWER THE SECOND PART OF YOUR
3 QUESTION, IT'S SOMETIMES DIFFICULT EVEN WITH A BIOPSY TO SAY
4 FOR SURE THAT YOU GOT THE SITE OF THE TUMOR.

5 WHAT WE PATHOLOGISTS USUALLY NEED IS SOME OF THE
6 TISSUE, THAT IS THAT'S NORMAL, IN ADDITION TO THE CANCER
7 TISSUE, SO THAT WE CAN SEE NOT ONLY THE TUMOR, BUT THE
8 TRANSITION FROM THE CANCER TO THE NORMAL TISSUE FROM WHICH
9 IT ORIGINATED.

10 AND SOMETIMES, THE BIOPSY DOESN'T INCLUDE THAT,
11 ESPECIALLY IN THE CASE OF VERY SMALL BIOPSIES LIKE FINE
12 NEEDLE ASPIRATIONS THAT ARE COMMONLY USED, AND BRONCHIAL
13 BIOPSIES. THERE'S VERY SMALL TISSUES TO MEASURE, IN
14 MILLIMETERS.

15 Q. DO CANCERS LOOK THE SAME? HOW DOES A CANCER --
16 CAN YOU DISTINGUISH WHERE IN THE BODY A CANCER STARTED BY
17 HOW IT LOOKS UNDER THE MICROSCOPE?

18 A. SOMETIMES, BUT NOT VERY OFTEN.
19 THE FACT IS, MANY DIFFERENT ORGANS OF THE BODY
20 WILL YIELD CANCERS THAT HAVE THE SAME CELL TYPE. WHEN THAT
21 OCCURS, AND IF YOU DON'T HAVE THAT TRANSITION BETWEEN THE
22 CANCER AND THE NORMAL TISSUE WHICH I MENTIONED, YOU JUST
23 SIMPLY CANNOT BE SURE WHERE THE CANCER ORIGINATED FROM.
24 IT'S A RATHER IMPORTANT POINT THAT I TRIED TO
25 TEACH POSTGRADUATE STUDENTS AND OTHER STUDENTS OF PATHOLOGY,
26 THAT IF YOU CAN'T SEE THE ORIGIN OF A TUMOR, YOU SHOULDN'T
27 USE A SIMPLE DECLARATIVE SENTENCE AND SAY THAT IT ORIGINATED
28 AT A PARTICULAR SITE. YOU SHOULD PHRASE THE DIAGNOSIS SO
JUDITH ANN OSSA, CSR NO. 2310

0014

1 THE CLINICIAN KNOWS THAT YOU DON'T KNOW FOR SURE WHERE THE
2 TUMOR ORIGINATED FROM.
3 Q. HOW OFTEN -- STRIKE THAT.
4 WHEN YOU OR A DOCTOR HAS A BIOPSY THAT WAS
5 OBTAINED FROM A SPECIFIC LOCATION IN THE BODY, AS I
6 UNDERSTAND WHAT YOU SAID, SOMETIMES THERE ARE THINGS
7 ATTACHED TO THE TUMOR THAT ALLOW YOU TO DETERMINE WHERE IT
8 MIGHT HAVE STARTED?
9 A. YES, SIR.
10 Q. WHEN YOU DON'T HAVE INFORMATION LIKE THAT BUT YOU
11 KNOW FROM WHERE IN THE BODY THE BIOPSY WAS OBTAINED, DOES
12 THAT -- HOW OFTEN DOES THAT GIVE YOU ENOUGH INFORMATION TO
13 DETERMINE WHETHER THAT'S THE PLACE WHERE THE CANCER STARTED?
14 A. WELL, PRACTICALLY NEVER. THE FACT IS THAT WE
15 PATHOLOGISTS, AS I SAID BEFORE, HAVE TO HAVE AN INDEPENDENT
16 OPINION TO MAKE A VALUABLE DIAGNOSTIC JUDGMENT.
17 WE CANNOT TAKE THE CLINICAL INFORMATION PROVIDED
18 TO US AND RUBBER-STAMP IT IN TERMS OF THAT BEING THE
19 PROBABLE SITE OF ORIGIN. WE MUST CRITICALLY EXAMINE THE
20 QUESTION.
21 Q. WHAT INFORMATION OR WHAT TOOLS DO YOU USE TO
22 CONDUCT THAT EXAMINATION?
23 A. WELL, AS I SAID, IN THE FINAL ANALYSIS, IF YOU
24 DON'T HAVE A TRANSITION OF THE NORMAL TISSUE WITH THE
25 CANCER, YOU CAN NEVER BE 100 PERCENT CERTAIN OF THE SITE OF
26 ORIGIN.
27 BUT ON THE OTHER HAND, OF COURSE, WHEN WE'RE NOT
28 SURE, USUALLY THE SURGEON TURNS UP IN OUR OFFICE OR AT LEAST
JUDITH ANN OSSA, CSR NO. 2310

0015

1 ON THE TELEPHONE AND WE DISCUSS THE CASES WITH THEM FROM
2 THEIR STANDPOINT.
3 AND SOMETIMES, WE CAN REVIEW THE CT'S OR THE
4 X-RAYS AND WE CAN TAKE THAT INFORMATION, AND IN DISCUSSING
5 THE CASE WITH THE CLINICIANS, WE CAN SAY, "WELL, YOU KNOW,
6 YOUR DIAGNOSIS SEEMS TO BE WELL-FOUNDED OR NOT," AND YET WE
7 CANNOT NECESSARILY SAY IT'S DEFINITELY CORRECT, BECAUSE IN
8 THE FINAL ANALYSIS, THOSE OTHER LINES OF EVIDENCE ARE NOT
9 WITHIN OUR DIRECT CONTROL TO ASSURE THEIR QUALITY AND
10 MEANING.
11 Q. WHAT ABOUT A PATIENT'S HISTORY OR SYMPTOMS OR A
12 PHYSICAL EXAMINATION CONDUCTED BY A DOCTOR, WHAT CAN THAT
13 TELL YOU AS A PATHOLOGIST ABOUT WHERE IN THE BODY A CANCER
14 MIGHT HAVE STARTED?
15 A. WELL, IN EASY CASES, A LOT. I MEAN, YOU KNOW, IF
16 THE DERMATOLOGIST TELLS US HE'S GOT A PIGMENTED LESION OF
17 THE SKIN AND WE HAVE A SLIDE OF THE SKIN THAT SHOWS
18 MALIGNANT MELANOMA, I MEAN, THAT'S VERY HELPFUL.
19 IT'S JUST THAT, UNHAPPILY, MOST OF THE CANCERS
20 THAT WE'RE DEALING WITH ARE DEEPER IN THE BODY.

21 Q. AND HOW OFTEN, WITH RESPECT TO TUMORS THAT ARE
22 SUSPECTED OF BEING EITHER IN OR OF THE LUNG, DO YOU HAVE
23 BIOPSY MATERIAL OBTAINED FROM EITHER A BRONCHOSCOPY OR
24 ANOTHER TYPE OF INVASIVE PROCEDURE?
25 A. WELL, USUALLY. I WOULDN'T SAY ALWAYS. THE
26 UNIVERSITIES WITH WHICH I'VE BEEN AFFILIATED, IT'S BEEN THE
27 POLICY TO USE BRONCHIAL BRUSHINGS AND WASHINGS, CYTOLOGIES
28 FOR THE DIAGNOSIS OF BRONCHOGENIC CARCINOMA, AND ALSO TO DO
JUDITH ANN OSSA, CSR NO. 2310

0016

1 BIOPSIES EVEN IF NO CANCER IS OBSERVED IN THE BRONCHUS.
2 THOSE TECHNIQUES ARE HIGHLY RELIABLE.
3 Q. I WANT TO ASK YOU NOW, DOCTOR, TO TALK
4 SPECIFICALLY ABOUT MS. HENLEY'S SITUATION.
5 BUT JUST BRIEFLY, BEFORE I DO, LET ME ASK YOU
6 ABOUT DIFFERENT CELL TYPES OF CANCER.
7 WE HAVE HEARD A LITTLE BIT ALREADY ABOUT
8 SOMETHING CALLED SMALL CELL CARCINOMA.
9 IN GENERAL TERMS, WHY OR HOW ARE CANCERS
10 DISTINGUISHED BY CELL TYPE?
11 A. THE MAIN THRUST OF DISTINGUISHING CELL TYPES OF
12 CANCERS CAME FROM THE WORLD HEALTH ORGANIZATION AND A
13 NORWEGIAN PATHOLOGIST BY THE NAME OF KREYRG, K-R-E-Y-R-G.
14 THEY WANTED TO SEE IF THE CELL TYPES THAT HAD BEEN
15 PREVIOUSLY DESCRIBED BY OTHERS REFLECTED DIFFERENCES IN
16 THEIR BIOLOGY AND POSSIBLY THEIR CAUSATION.
17 SO THEY DEVELOPED A SCHEME OF DESCRIBING CERTAIN
18 CELL TYPES AND PROPOSED THAT PATHOLOGISTS THROUGHOUT THE
19 WORLD SHOULD USE IT SO THAT, IN THE FUTURE, WE COULD FIND
20 OUT IF THE VARIOUS CELL TYPES REFLECTED DIFFERENT BIOLOGIC
21 PATTERNS OF BEHAVIOR.
22 Q. AND BY THAT, YOU MEAN WHETHER THEY BEHAVED
23 DIFFERENTLY AFTER THEY HAVE BEEN FOUND?
24 A. YES, SIR. YOU KNOW, FOR EXAMPLE, EVERYBODY KNEW
25 THAT SMALL CELL ANAPLASTIC CARCINOMAS OF BRONCHIAL ORIGIN
26 HAD A TERRIBLE PROGNOSIS.
27 BUT THE QUESTION WAS: WHAT ABOUT THE OTHER CELL
28 TYPES, THE ADENOCARCINOMAS, THE SQUAMOUS CELLS. THE
JUDITH ANN OSSA, CSR NO. 2310

0017

1 DIFFERENCES WERE NOT ABSOLUTELY APPARENT WHEN KREYRG AND
2 OTHERS WANTED TO DISTINGUISH THESE VARIOUS CELL TYPES.
3 SO THEY SET UP THE CLASSIFICATION SCHEME, AND
4 IT'S BEEN VERY USEFUL.
5 Q. WHEN A DOCTOR IS TRYING TO DIAGNOSE CANCER IN A
6 PATIENT, IS IT IMPORTANT TO DETERMINE WHAT THE CELL TYPE OF
7 THAT CANCER IS?
8 A. WELL, FROM MY STANDPOINT, YES. IT'S EXTREMELY
9 IMPORTANT TO KNOW THE CELL TYPE. BUT IT'S ALSO EXTREMELY
10 IMPORTANT TO KNOW FROM WHERE THE TUMOR ORIGINATED. BECAUSE
11 AS WE HAVE ALREADY HINTED AT THIS MORNING, THE VARIOUS
12 ORGANS OF THE BODY CAN GIVE RISE TO THE SAME CELL TYPES OF
13 CANCER. AND YOU CERTAINLY WANT TO TREAT THE PRIMARY SITE
14 SPECIFICALLY, IF YOU CAN.
15 Q. WITH RESPECT TO WHAT WE HAVE REFERRED TO AS SMALL
16 CELL CANCER OR SMALL CELL CARCINOMA, I THINK YOU EVEN SAID
17 SMALL CELL ANAPLASTIC CARCINOMA THAT IS GENERALLY THE SAME.
18 I REALIZE THERE ARE PROBABLY MORE PRECISE WAYS TO
19 DESCRIBE IT, BUT IS THAT GENERALLY REFERRED TO AS THE SAME
20 TYPE OF TUMOR?
21 A. YES, IN A GENERAL WAY. AND THEY CAN ALL BE
22 REGARDED AS SYNONYMOUS, I THINK, FOR THE PURPOSES OF THIS
23 DISCUSSION.

24 I BELIEVE THAT IT'S PREFERABLE TO USE THE TERM
25 "SMALL CELL ANAPLASTIC CARCINOMA" WHEN WE'RE TALKING ABOUT
26 TUMORS OF BRONCHOGENIC ORIGIN, BECAUSE THERE ARE LOTS OF
27 OTHER SMALL CELL TUMORS THAT ARE UNRELATED TO BRONCHOGENIC
28 CARCINOMA WHICH MAY BE CONFUSED WITH IT.

JUDITH ANN OSSA, CSR NO. 2310

0018

1 Q. WHEN YOU SAY "BRONCHOGENIC ORIGIN," YOU MEAN A
2 TUMOR THAT ACTUALLY STARTS GROWING IN THE LUNG?

3 A. NOT ONLY IN THE LUNG, BUT IN THE LARGER BRANCHES
4 OF THE WINDPIPE OR THE TRACHEA.

5 WE'RE TALKING, FOR THE MOST PART -- NOT
6 EXCLUSIVELY, BUT FOR THE MOST PART, WE'RE TALKING ABOUT
7 TUMORS THAT ORIGINATED CLOSE TO THE CENTER OF YOUR CHEST.
8 WE CALL THEM CENTRALLY LOCATED (INDICATING).

9 THEY DON'T ORIGINALLY ORIGINATE FROM THE
10 BREATHING TUBES FARTHER OUT IN THE LUNG.

11 Q. AND WOULD THAT BE WITHIN THE CENTER -- WHEN YOU
12 SAY "CENTER OF THE CHEST," DO YOU MEAN IN THE LUNG OR OUT OF
13 THE LUNG?

14 A. WELL, SOME OF THEM ORIGINATE IN THE BRONCHI,
15 OUTSIDE OF THE LUNG, BUT MOST, JUST ABOUT WHERE THE BRONCHI
16 ENTER INTO THE LUNG, THE REGION THAT WE CALL THE HILUM.

17 Q. WOULD A TUMOR THAT WAS IN THE BRONCHI BE
18 DESCRIBED OR BE OBSERVABLE AS AN ENDOBRONCHIAL LESION?

19 A. AS A RULE, YES, BUT NOT INVARIABLY.

20 Q. AND "ENDOBRONCHIAL" MEANING INSIDE THE AIRWAY?

21 A. YES, SIR.

22 Q. NOW, HOW IS IT POSSIBLE WHEN YOU LOOK AT A TUMOR
23 UNDER THE MICROSCOPE TO DETERMINE WHAT CAUSED IT BY LOOKING
24 AT IT?

25 A. NO. WHAT WE SEE ARE THE CELLS THAT COMPOSE THE
26 CANCER, AND WE HAVE NO IDEA ABOUT CAUSATION FROM LOOKING AT
27 THE CELLS THEMSELVES.

28 Q. WOULD THE CELLS LOOK THE SAME? IF YOU HAD TWO
JUDITH ANN OSSA, CSR NO. 2310

0019

1 TUMORS OF THE SAME CELL TYPE BUT THAT HAD BEEN CAUSED BY
2 DIFFERENT THINGS, WOULD THEY LOOK THE SAME UNDER THE
3 MICROSCOPE?

4 A. YES, SIR.

5 Q. NOW, LET ME ASK YOU SPECIFICALLY, DOCTOR, ABOUT
6 MS. HENLEY.

7 AT MY REQUEST AND THE REQUEST OF ONE OF MY LAW
8 PARTNERS, DID YOU LOOK AT THE CYTOLOGY MATERIALS AND THE
9 BIOPSY MATERIAL TAKEN FROM MS. HENLEY?

10 A. YES, SIR, I DID.

11 Q. DID YOU ALSO HAVE AN OPPORTUNITY TO REVIEW
12 MEDICAL RECORDS?

13 A. SUBSEQUENT TO THE ORIGINAL -- SUBSEQUENT TO THE
14 ORIGINAL EXAMINATION OF THE SLIDES THAT YOU DESCRIBED, I DID
15 REVIEW THE MEDICAL RECORDS.

16 Q. AND THEN THE X-RAYS AND THE CT SCAN?

17 A. YES. THAT WAS AT A STILL LATER DATE.

18 Q. IS THERE A REASON THAT YOU LOOKED AT THINGS IN
19 THAT ORDER?

20 A. YES.

21 Q. CAN YOU EXPLAIN THAT FOR ME?

22 I MEAN, LET ME ASK YOU THIS: IS IT YOUR STANDARD
23 PRACTICE TO LOOK AT THAT KIND OF INFORMATION IN THAT ORDER?

24 A. IT IS.

25 Q. WHY IS THAT?

26 A. I THINK IT'S VITALLY IMPORTANT THAT WE

27 PATHOLOGISTS DEVELOP INDEPENDENT DIAGNOSTIC OPINIONS,
28 INDEPENDENT OF INFORMATION SUPPLIED TO US. IT PROVIDES US
JUDITH ANN OSSA, CSR NO. 2310

0020

1 WITH THE OBJECTIVITY THAT WE REALLY NEED IN OUR WORK.
2 FOR THAT REASON, IT'S ALWAYS BEEN MY PRACTICE,
3 AND I'VE ALWAYS TAUGHT OTHERS, THAT THEY SHOULD FIRST LOOK
4 AT THE ANATOMICAL MATERIAL, WITHOUT A CLINICAL HISTORY, AND
5 THEY SHOULD DEVELOP A PRELIMINARY PATHOLOGIC DIAGNOSIS.
6 AND THEN, VERY IMPORTANTLY, THEY SHOULD GET ALL
7 THE CLINICAL INFORMATION THAT'S AVAILABLE TO THEM SO THAT
8 THEY CAN CRITIQUE THEIR PATHOLOGIC DIAGNOSIS AND MAKE SURE
9 IT MAKES SENSE FROM A CLINICAL STANDPOINT.

10 THAT SEQUENCE ASSURES US OF REASONABLE
11 INDEPENDENCE OF JUDGMENT, BUT IT DOESN'T DEPRIVE US IN THE
12 FINAL ANALYSIS OF LOOKING AT THE PATIENT AS A PERSON RATHER
13 THAN SIMPLY SOMETHING UNDER THE MICROSCOPE.

14 Q. AND IN THIS INSTANCE, DR. HENSLEY, IS THERE ANY
15 DOUBT THAT MS. HENLEY HAD A SMALL CELL CARCINOMA?

16 A. NONE WHATEVER.

17 Q. IS THERE ANY WAY TO DETERMINE WITH REASONABLE
18 CERTAINTY WHERE IN HER BODY IT BEGAN?

19 A. AT THIS POINT, I THINK YOU CAN SAY THAT IT WOULD
20 BE IMPOSSIBLE. THE PROBLEM THAT WE'RE CONFRONTED WITH ON
21 THIS PARTICULAR CASE --

22 MS. CHABER: YOUR HONOR, I WOULD JUST OBJECT TO
23 THE NARRATIVE. I THINK HE ANSWERED THE QUESTION.

24 I MOVE TO STRIKE.

25 THE COURT: I DON'T --

26 MR. OHLEMEYER: Q. DOCTOR --

27 THE COURT: I DON'T THINK HE GOT STARTED VERY
28 FAR ON ANYTHING BEYOND THE ANSWER TO THE QUESTION. I'M

JUDITH ANN OSSA, CSR NO. 2310

0021

1 GOING TO LEAVE IT IN.

2 BUT YOU CAN GO AHEAD. ASK THE NEXT QUESTION.

3 MR. OHLEMEYER: Q. DOCTOR, CAN YOU DESCRIBE
4 FOR ME THE BASIS OF YOUR OPINION THAT IT'S NOT POSSIBLE TO
5 DETERMINE WITH REASONABLE CERTAINTY WHERE THIS CANCER
6 BEGAN.

7 A. YES. I MENTIONED BEFORE, THE FIRST PRINCIPLE, IF
8 YOU'RE GOING TO MAKE A DIAGNOSIS IN A CASE LIKE THIS, IS TO
9 LOOK WHERE YOU THINK THE TUMOR ORIGINATED AND TO BIOPSY IT
10 AND TO GET THE CYTOLOGY FROM THAT LOCATION.

11 YOU CAN THEN EITHER HAVE A SHOT AT LOOKING AT
12 THAT TRANSITION ZONE THAT I DESCRIBED AND PROVE THAT THAT'S
13 THE SITE OF ORIGIN, OR CONTRARYWISE.

14 Q. AND WOULD THAT BE THE TRANSITION BETWEEN NORMAL
15 TISSUE AND CANCEROUS TISSUE?

16 A. YES, SIR.

17 Q. IN THIS CASE, WHERE OR FROM WHAT PART OF THE BODY
18 WAS THE TISSUE OBTAINED FROM WHICH THE BIOPSY WAS PREPARED?

19 A. THE PATIENT'S MEDIASTINUM.

20 Q. WAS THERE TISSUE BIOPSIED IN THIS CASE FROM THE
21 LUNG?

22 A. NO.

23 Q. WAS THERE ANY LYMPH NODE TISSUE IN THE BIOPSY
24 THAT WAS PREPARED IN THIS CASE?

25 A. NO.

26 Q. IN YOUR OPINION, DOCTOR, IS THERE ANY
27 SIGNIFICANCE TO THE FACT THAT THERE WAS NO LYMPH NODE TISSUE
28 BIOPSIED WITH RESPECT TO THE QUESTION OF WHERE THIS CANCER

JUDITH ANN OSSA, CSR NO. 2310

0022

1 MIGHT HAVE STARTED?

2 A. YES.

3 Q. CAN YOU EXPLAIN THAT FOR US.

4 A. WELL, FROM THE PATHOLOGIC STANDPOINT, GIVEN THE
5 LOCATION OF THE PROBLEM, WE'RE DEALING WITH A DIFFERENTIAL
6 DIAGNOSIS OF BRONCHOGENIC CARCINOMA VERSUS CANCER THAT
7 SPREAD TO THE CHEST. AND THE FACT THAT BRONCHOGENIC
8 CARCINOMA IS FIRST CARCINOMA IS TOO IMPORTANT TO DEAL WITH
9 HERE.

10 HOW DOES IT SPREAD OUTSIDE OF THE BRONCHUS?

11 WELL, IT SPREADS TO THE LYMPH NODES, TYPICALLY,
12 AS ANAPLASTIC CARCINOMAS OF LYMPH NODES, PRESENT AS MULTIPLE
13 ENLARGED LYMPH NODES AROUND THE BRONCHUS WHERE THE CANCER
14 IS.

15 IN FACT, THE LYMPH NODES ARE USUALLY THE
16 PREDOMINANT ANATOMIC STRUCTURE THAT'S SEEN, THE ABNORMAL
17 LYMPH NODES THAT CONTAIN THE CANCER.

18 Q. LET ME INTERRUPT YOU THERE AND ASK YOU TO EXPLAIN
19 A COUPLE OF THINGS YOU SAID.

20 WHEN YOU SAY SMALL CELL CARCINOMA OF THE LUNG
21 TYPICALLY SPREADS TO THE LYMPH NODES, WHAT DO YOU MEAN BY
22 "TYPICALLY"?

23 A. ALMOST ALWAYS IN SMALL CELL ANAPLASTIC CARCINOMA
24 OF THE LUNG, THE REGIONAL LYMPH NODES IN THE CHEST SHOW A
25 MULTITUDE OF METASTATIC LESIONS THAT EVEN ARE ENLARGED MORE
26 THAN THAT.

27 IT'S NOT UNCOMMON FOR THESE METASTATIC LESIONS TO
28 OCCUR IN LYMPH NODES WITHIN THE ABDOMEN AND NECK AS WELL.

JUDITH ANN OSSA, CSR NO. 2310

0023

1 Q. IS THERE ANY EVIDENCE IN THIS CASE OF THE SPREAD
2 TO REGIONAL LYMPH NODES OR LYMPH NODES IN THE ABDOMEN OR
3 NECK?

4 A. NO.

5 Q. AND WHAT, IF ANYTHING, DOES THAT TELL YOU ABOUT
6 WHERE THE TUMOR MIGHT HAVE STARTED OR IS LIKELY TO HAVE
7 STARTED?

8 A. WELL, THE FAILURE TO OBSERVE MULTIPLE NODAL
9 METASTASES IN THIS CASE IS SO UNUSUAL THAT IT RAISES THE
10 QUESTION OF WHETHER THE DIAGNOSIS OF BRONCHOGENIC CARCINOMA
11 IS CORRECT. MORE THAN THAT, I COULDN'T SAY.

12 Q. WHEN YOU SAY IT'S SO UNUSUAL, IN RELATION TO WHAT
13 IS IT SO UNUSUAL?

14 A. WELL, THE TYPICAL BEHAVIOR OF SMALL CELL
15 ANAPLASTIC CARCINOMA, AS I SAID, THE GREAT MAJORITY OF CASES
16 HAVE MULTIPLE LYMPH NODES THAT ARE POSITIVE FOR CANCER, THAT
17 ARE READILY VISUALIZED BY X-RAY OR BY CT STUDIES OF THE
18 CHEST.

19 IN FACT, PRIOR TO THE RECOGNITION OF THAT CELL
20 TYPE OF CANCER IN THE 1920S, MANY PEOPLE DIAGNOSED THESE
21 CANCERS OF THE LUNG AS LYMPHOMA BECAUSE THE PREDOMINANT
22 LESION WAS IN THE LYMPH NODES.

23 SO THIS LADY DIDN'T SHOW THAT. THE X-RAY
24 PICTURES AND THE OTHER FEATURES HERE WERE TOTALLY DIFFERENT.

25 Q. BASED ON YOUR EXPERIENCE, DOCTOR, AND YOUR
26 BACKGROUND, IF MS. HENLEY HAD A CANCER THAT HAD STARTED
27 GROWING IN HER LUNG, WOULD YOU HAVE EXPECTED TO FIND
28 EVIDENCE OF IT IN THE LYMPH NODES?

JUDITH ANN OSSA, CSR NO. 2310

0024

1 A. ABSOLUTELY.

2 Q. ARE THERE OTHER PARTS OF THE BODY, INCLUDING

3 THINGS WITHIN THE MEDIASTINUM, IN WHICH SMALL CELL CARCINOMA
4 CAN BEGIN GROWING?

5 A. YES.

6 Q. AND WHEN SMALL CELL CARCINOMA BEGINS GROWING AT
7 ANY POINT IN THE BODY, IS IT POSSIBLE OR TYPICAL FOR IT TO
8 SPREAD TO OTHER PARTS OF THE BODY?

9 A. YES, SIR.

10 Q. IS THERE ANY WAY TO DETERMINE WITH REASONABLE
11 CERTAINTY, DOCTOR -- LET ME REPHRASE THE QUESTION.

12 I WANT TO FOCUS NOW ON THE LUNG AS OPPOSED TO
13 WHERE ELSE IN THE BODY THE CANCER MIGHT HAVE STARTED.

14 CAN YOU DETERMINE OR COME TO AN OPINION WITH
15 REASONABLE CERTAINTY AS TO WHETHER THIS CANCER STARTED IN
16 THE LUNG?

17 A. THERE'S NO EVIDENCE THAT IT STARTED IN THE LUNG.

18 Q. AND CAN YOU EXPLAIN THE BASIS OF THAT OPINION FOR
19 ME.

20 A. WELL, AS I SAID, THE FIRST THING ONE DOES IS TO
21 LOOK WHERE YOU THINK THE TUMOR IS, AND THAT WAS DONE IN THIS
22 CASE, AND A BRONCHOSCOPY WAS DONE TO LOOK FOR CANCER IN THE
23 LEFT BRONCHIAL REGION, AND NONE WAS FOUND.

24 FURTHERMORE, ALL OF THE CT STUDIES AND ALL OF THE
25 X-RAYS FAILED TO DEMONSTRATE ANY INVOLVEMENT OF THE LUNG AT
26 ALL.

27 WELL, GIVEN THE FACT THAT THERE WAS SIMPLY NO
28 RADIOGRAPHIC EVIDENCE AND THERE'S NO EVIDENCE FROM THE

JUDITH ANN OSSA, CSR NO. 2310

0025

1 BRONCHOSCOPY THAT THE LUNG WAS INVOLVED, I WOULD HAVE TO SAY
2 THAT, IN MY JUDGMENT, THE LUNG SIMPLY WASN'T INVOLVED.

3 Q. LET ME ASK YOU, DOCTOR: IN YOUR EXPERIENCE, HOW
4 OFTEN DOES A BRONCHOSCOPY PROVIDE A POSITIVE BIOPSY IN CASES
5 OF SMALL CELL CARCINOMA THAT BEGINS GROWING IN THE LUNG?

6 A. I CAN'T GIVE YOU AN EXACT FIGURE, BUT IN THE
7 GREAT MAJORITY OF CASES, IT'S POSITIVE.

8 Q. IN YOUR EXPERIENCE, DOCTOR, HOW OFTEN DOES A CT
9 SCAN OR AN X-RAY DEMONSTRATE INVOLVEMENT OF THE LUNG IN
10 CASES IN WHICH A SMALL CELL CARCINOMA BEGINS GROWING IN THE
11 LUNG?

12 A. WELL, WHAT THE CT AND X-RAYS DEMONSTRATE ARE
13 MULTIPLE MASSIVELY ENLARGED LYMPH NODES. THEY'RE NOT VERY
14 GOOD AT FINDING THE PRIMARY TUMOR IN CASES OF SMALL CELL
15 CANCER, BUT THEY'RE VERY GOOD IN PICKING OUT LYMPH NODE
16 INVOLVEMENT THAT MAY SUGGEST THE PRESENCE OF SUCH A CANCER.

17 Q. ARE THERE OTHER FINDINGS OR ABNORMALITIES THAT
18 YOU'VE OBSERVED WITH ANY FREQUENCY FROM BRONCHOSCOPIES IN
19 PATIENTS WHO HAVE A PRIMARY CARCINOMA THAT STARTS GROWING IN
20 THE LUNG?

21 A. WOULD YOU REPEAT THE FIRST PART.

22 Q. YES. IN YOUR EXPERIENCE, DOCTOR, ARE THERE OTHER
23 FINDINGS OR ABNORMALITIES THAT ARE TYPICALLY ASSOCIATED --
24 THAT CAN BE DEMONSTRATED BY BRONCHOSCOPY THAT ARE TYPICALLY
25 ASSOCIATED WITH A SMALL CELL CARCINOMA THAT STARTS GROWING
26 IN THE LUNG?

27 A. WELL, USUALLY, YOU CAN FIND THE PRIMARY TUMOR --
28 I MEAN, ORDINARILY, YOU FIND AN AREA WHERE THE BRONCHUS IS

JUDITH ANN OSSA, CSR NO. 2310

0026

1 ULCERATED OR HAS A LITTLE THICKENING OF THE MUCUS MEMBRANE,
2 THAT SORT OF THING.

3 AS I SAID, YOU KNOW, THE BIOPSY IS USUALLY
4 POSITIVE.

5 Q. IS THERE ANY EVIDENCE OF THAT KIND OF ULCERATION

6 OR THICKENING IN THIS CASE?

7 A. NO, SIR. BUT ON THE OTHER HAND, WE NEVER GOT ANY
8 TISSUE FROM THAT BRONCHIAL SITE. IT'S UNFORTUNATE THAT WE
9 CAN'T ANSWER THAT QUESTION.

10 Q. DOCTOR, HOW OFTEN -- STRIKE THAT.

11 IN YOUR EXPERIENCE, IN CASES IN WHICH A SMALL
12 CELL CARCINOMA IS DIAGNOSED TO HAVE STARTED GROWING IN THE
13 LUNG, AT THE TIME IT'S DIAGNOSED, ARE THERE OTHER PARTS OF
14 THE BODY TO WHICH IT'S TYPICALLY ALREADY SPREAD?

15 A. YES. IT MAY NOT BE IMMEDIATELY EVIDENT, BUT IT'S
16 VERY COMMON TO FIND LYMPH NODE INVOLVEMENT IN THE CHEST, BUT
17 ALSO ALONG THE UPPER AND LOWER BORDERS OF THE PANCREAS AND
18 IN THE ADRENAL GLANDS.

19 SO IT'S CUSTOMARY WHEN YOU'RE MAKING A DIAGNOSIS
20 ON SUCH A PATIENT TO LOOK AT THE CT'S FOR LESIONS IN THOSE
21 LOCATIONS.

22 THAT WAS DONE IN THIS CASE, AND THERE WAS NO
23 EVIDENCE OF NODAL METASTASES, NOR EVIDENCE OF INVOLVEMENT OF
24 THE ADRENAL GLANDS IN THIS PATIENT.

25 Q. WHAT ARE SOME OF THE OTHER PARTS OF THE BODY
26 WHERE A SMALL CELL CARCINOMA CAN START?

27 A. WELL, PRACTICALLY ANY EPITHELIAL ORGAN MAY BE THE
28 SITE OF ORIGIN OF THE SMALL CELL CANCER. IF WE LOOK AT

JUDITH ANN OSSA, CSR NO. 2310

0027

1 THOSE WHICH ARE DIFFICULT TO DIAGNOSE AND MAY BE CONFUSED
2 WITH BRONCHOGENIC CARCINOMA, I WOULD SAY THE MOST COMMON IS
3 CARCINOMA OF THE PANCREAS OF SMALL CELL TYPE.

4 THAT ORGAN, AS I MENTIONED BEFORE, IS SORT OF
5 HIDDEN FROM VIEW. IT'S HARD TO GET A GOOD PICTURE OF THE
6 PANCREAS. SO SOMETIMES IT FIRST PRESENTS AS METASTATIC
7 DISEASE TO THE LYMPH NODES AND TO THE LUNG -- THE LYMPH
8 NODES IN THE CHEST AND TO THE LUNG.

9 A TUMOR THAT HAS TO BE BROUGHT INTO QUESTION IN
10 THIS PARTICULAR CASE IS THE RARE TUMOR KNOWN AS SMALL CELL
11 CARCINOMA OF THE THYMUS GLAND.

12 Q. WHY IS IT THAT THAT'S A CONSIDERATION IN THIS
13 CASE?

14 A. WELL, AS I SAID, THE SURGEON BIOPSIED THE
15 MEDIASTINUM. THE FACT IS THE THYMUS GLAND IS LOCATED IN THE
16 MEDIASTINUM. THE TISSUE THAT WE GOT CONTAINED ONLY FAT, NO
17 EVIDENCE OF LYMPH NODE TISSUE.

18 AND THE THYMUS GLAND, IN PERSONS OF THIS LADY'S
19 AGE, FREQUENTLY ARE COMPOSED CHIEFLY OF FAT AND OF FIBROUS
20 TISSUE.

21 OTHER REASONS INCLUDE THE IMPORTANT CONSIDERATION
22 THAT THIS WAS A SINGLE MASS, AT LEAST TO MY EYE, LOOKING AT
23 THE CT, SOMEWHAT LOBULATED.

24 Q. CAN I ASK YOU TO EXPLAIN THAT.

25 WHAT DO YOU MEAN BY A "SINGLE MASS, SOMEWHAT
26 LOBULATED"?

27 A. WELL, METASTATIC CANCER OF BRONCHOGENIC ORIGIN OF
28 SMALL CELL TYPE --

JUDITH ANN OSSA, CSR NO. 2310

0028

1 Q. LET ME INTERRUPT YOU THERE.

2 DO YOU MEAN A CANCER THAT HAD STARTED IN THE LUNG
3 AND SPREAD SOMEWHERE ELSE?

4 A. YES. YES, SIR. I'M GLAD YOU CLARIFIED THAT.

5 WELL, AS I SAID BEFORE, IT SPREADS TO A NUMBER OF
6 LYMPH NODES. SO USUALLY, WE'RE CONFRONTED WITH A FAIRLY
7 LARGE NUMBER OF DISCRETE LYMPH NODES OR LYMPH NODES THAT ARE
8 MATTED TOGETHER BECAUSE OF CANCER, BUT AT LEAST THEY'RE

9 SEPARATE LUMPS. THEY'RE MASSES.

10 BUT THYMIC LESIONS TEND TO BE SOLITARY, AND
11 THEY'RE LOCATED IN ESSENTIALLY WHERE THIS LADY HAD HER MASS,
12 NAMELY, THE MEDIASTINUM AND RETROSTERNAL -- THE RETROSTERNAL
13 SPACE.

14 Q. TELL US WHAT YOU MEAN BY "THE RETROSTERNAL SPACE
15 OF THE MEDIASTINUM."

16 A. WELL, YOU KNOW, YOUR BREASTBONE AND STERNUM GOES
17 FROM ABOUT HERE TO ABOUT HERE (INDICATING). IT'S THE BONE,
18 THE FIRM BONE THAT YOU CAN EASILY FEEL TO WHICH YOUR RIBS
19 ARE ATTACHED.

20 THE RETROSTERNAL SPACE IS THAT SPACE JUST BEHIND
21 THE STERNUM. AND IF YOU WANT TO FIND THE THYMUS GLAND IN
22 THE HUMAN BEING, THAT IS PRECISELY WHERE YOU LOOK, BECAUSE
23 THAT'S THE USUAL LOCATION OF THE THYMUS, BEARING IN MIND
24 THAT IT CAN BE QUITE IRREGULARLY SHAPED AND IT CAN BE FAIRLY
25 EXTENSIVE.

26 Q. NOW, IS THAT SPACE SOMETHING THAT'S IN THE LUNG?

27 A. NO, SIR.

28 Q. SEPARATE FROM THE LUNG?

JUDITH ANN OSSA, CSR NO. 2310

0029

1 A. SEPARATE FROM THE LUNG.

2 Q. THERE HAS BEEN SOME DISCUSSION THIS MORNING AND
3 EARLIER IN THE CASE ABOUT SOMETHING CALLED THE HILAR
4 REGION.

5 IS THAT A PHRASE OR A TERM WITH WHICH YOU'RE
6 FAMILIAR?

7 A. YES, SIR.

8 Q. WHAT IS THE HILAR REGION OF THE LUNG, OR ANY
9 OTHER PART OF THE BODY?

10 A. WELL, THE WORD "HILUM" OR "HILUS" CAN BE DEFINED
11 AS AN INDENTATION IN AN ORGAN THROUGH WHICH NOURISHING BLOOD
12 VESSELS, IN THE CASE OF THE LUNG, THE WINDPIPE, ALSO
13 PASSES.

14 THE HILUM IS NOT PART OF THE LUNG. IT'S A REGION
15 WHERE THERE'S A DEPRESSION IN WHICH THE HEART SITS. AND
16 THOSE BLOOD VESSELS GO IN AND OUT, AND THE MAIN STEM
17 BRONCHUS GOES IN AND OUT.

18 AND THAT PARTICULAR REGION IS NOT COVERED BY THE
19 GLISTENING TRANSPARENT MEMBRANE THAT WE CALL THE PLEURA. SO
20 IT'S REALLY -- IT REALLY REFERS TO THE CONFIGURATION -- YOU
21 COULD APPLY THE TERM "HILUM" TO THE INDENTATION OF A KIDNEY
22 BEAN, AND IT'S APPLIED ANATOMICALLY TO THE INDENTATION OF
23 THE KIDNEY.

24 I'M SURE MOST PEOPLE ARE FAMILIAR WITH THE
25 KIDNEY, YOU KNOW THE KIDNEY. THAT IS KIND OF THAT SHAPE.
26 ON ONE SIDE AND TOWARDS THE MIDDLE OF THE BODY, THERE IS AN
27 INDENTATION WHERE THE RENAL ARTERY AND VEIN GOES THROUGH.
28 WE CALL THAT THE HILUM OF THAT ORGAN.

JUDITH ANN OSSA, CSR NO. 2310

0030

1 Q. AND THE MEDIASTINUM IS WHAT?

2 A. THAT'S A PLACE --

3 Q. WHERE IS IT?

4 A. WELL, THE MEDIASTINUM IS THAT PLACE BETWEEN THE
5 LUNGS AND THE ROOT OF THE NECK, AND GOING DOWN TO THE
6 DIAPHRAGM, THAT SEPARATES THE ABDOMEN FROM THE CHEST.

7 THAT SPACE IS FILLED UP WITH THE HEART AND THE
8 GREAT VESSELS SPRINGING FROM THE HEART AND GOING TO THE
9 HEART. AND IT ALSO CONTAINS, OF COURSE, THE ESOPHAGUS OR
10 THE FOOD PIPE, AND THE TRACHEA AND BRONCHI IN THE UPPER
11 PORTION.

12 Q. DEFENDANT'S EXHIBIT 2790 PREVIOUSLY ADMITTED INTO
13 EVIDENCE, DOCTOR, IS THE X-RAY REPORT OF THE DEPARTMENT
14 IMAGING SERVICES OF THE CT SCAN AND THE X-RAYS PERFORMED ON
15 MS. HENLEY --

16 A. MM-HMM.

17 Q. -- IN JANUARY OF 1998.

18 IS THAT A RECORD YOU'VE PREVIOUSLY REVIEWED?

19 A. YES, I HAVE A FAIRLY GOOD RECOLLECTION OF IT.

20 Q. IN THAT REPORT, THERE IS A REFERENCE TO THE

21 ABSENCE OF ADENOPATHY, A-D-E-N-O-A-P --

22 A. T-H-Y.

23 Q. -- T-H-Y.

24 WHAT IS ADENOPATHY?

25 A. WELL, SIR, IT MEANS SIMPLY DISEASE OF THE LYMPH
26 NODES. BUT SPECIFICALLY, IN THE CONTEXT OF THE CHEST X-RAY
27 OR A CT OF THE CHEST, IT MEANS THAT THE LYMPH NODES ARE NOT
28 ENLARGED.

JUDITH ANN OSSA, CSR NO. 2310

0031

1 THAT'S AN EXTREMELY IMPORTANT POINT IN THIS
2 CASE. NOT ONLY IS THE MASS DESCRIBED TO BE MEDIASTINAL AND
3 EXTENDING TOWARD THE HILUM OF THE LUNG, BUT FURTHERMORE, THE
4 LYMPH NODES ARE NOT ENLARGED.

5 SO THIS ADDS STRENGTH TO THE HYPOTHESIS THAT THE
6 TUMOR COULD HAVE ORIGINATED FROM THE THYMUS GLAND AS OPPOSED
7 TO THE BRONCHUS.

8 Q. ARE THERE ANY OTHER FINDINGS OR CHARACTERISTICS
9 OF MS. HENLEY'S SITUATION THAT COMPARE OR CONTRAST TO A
10 TYPICAL CANCER THAT BEGINS GROWING IN THE LUNG OTHER THAN
11 THE ONES YOU'VE ALREADY MENTIONED?

12 A. NONE THAT I CAN THINK OF AT THIS MOMENT. I'M
13 PROBABLY OVERLOOKING SOMETHING. BUT FROM MY STANDPOINT AS A
14 PATHOLOGIST, I THINK WE'VE COVERED THE DIFFERENCES OF
15 ANATOMY.

16 Q. DOCTOR, LET ME ASK YOU TO ASSUME THAT THERE HAS
17 BEEN TESTIMONY IN THIS CASE THAT MOST OF THE TIME WHEN A
18 PATIENT IS DISCOVERED TO HAVE A SMALL CELL CARCINOMA, IT
19 TURNS OUT TO HAVE STARTED IN THE LUNG.

20 DOESN'T THAT -- OR DOES THAT SUGGEST TO YOU THAT
21 THIS IS A TUMOR THAT PROBABLY STARTED IN MS. HENLEY'S LUNG,
22 EVEN THOUGH IT WASN'T FOUND IN THE BRONCHOSCOPY OR
23 DEMONSTRATED ON THE X-RAY?

24 A. NO, ABSOLUTELY NOT.

25 Q. WHY NOT?

26 A. WELL, AS I SAID AT THE VERY BEGINNING, WE
27 PATHOLOGISTS HAVE TO HAVE AN INDEPENDENT JUDGMENT OF THE
28 MATERIAL THAT WE HAVE IN HAND TO EVALUATE, AND WE HAVE TO BE

JUDITH ANN OSSA, CSR NO. 2310

0032

1 VERY OBJECTIVE. WE CAN'T PLAY THE ODDS.

2 YOU KNOW, PLAYING THE ODDS MAY BE OKAY FOR
3 RECREATION, BUT NOT FOR DIAGNOSIS OF DISEASE IN A HUMAN
4 BEING. OUR OBLIGATION IS TO LOOK FOR THE EVIDENCE AND TO
5 INTERPRET IT. I CAN'T INTERPRET THE ODDS IN A PARTICULAR
6 CASE.

7 Q. IN ORDER TO TREAT A PATIENT IN MS. HENLEY'S
8 SITUATION, IS IT TYPICALLY NECESSARY TO DETERMINE PRECISELY
9 WHERE A CANCER OF THIS TYPE STARTED GROWING IN THE BODY?

10 A. WELL, THERE ARE TWO WAYS OF LOOKING AT THAT
11 QUESTION, BEFORE AND AFTER THE FACT OF DIAGNOSIS AND
12 TREATMENT.

13 I WOULD SAY THAT UP TO THE MOMENT YOU INITIATE
14 TREATMENT, YOU WANT TO MAKE AN EFFORT TO FIND OUT WHAT THE

15 CELL TYPE IS AND WHERE THE TUMOR ORIGINATED FROM, SO THAT
16 YOU CAN BE SURE THAT YOU SELECT THE RIGHT TREATMENT FOR THE
17 PATIENT.

18 IN THIS PARTICULAR CASE, WHERE IT'S BEEN
19 ESTABLISHED THAT SHE IS DEALING WITH A SMALL CELL CARCINOMA,
20 IT'S KIND OF AN ACADEMIC POINT WHETHER IT ORIGINATED IN THE
21 LUNG OR THE THYMUS FROM THE STANDPOINT OF THERAPY.

22 AS FAR AS WE KNOW TODAY, THE TREATMENT OF THE TWO
23 CANCERS WOULD BE EXACTLY THE SAME.

24 Q. AND IN NEITHER CASE WOULD SURGERY OR REMOVAL OF
25 THE TUMOR BE AN OPTION?

26 A. NO, I DON'T THINK THAT WOULD BE INDICATED.

27 MR. OHLEMEYER: ALL RIGHT. MAY I HAVE A MOMENT,
28 YOUR HONOR?

JUDITH ANN OSSA, CSR NO. 2310

0033

1 THE COURT: YES. WE'RE GOING TO TAKE OUR
2 MORNING RECESS ANYWAY.

3 DO YOU WANT TO DO IT NOW?

4 MR. OHLEMEYER: THAT'S FINE.

5 THE COURT: OKAY. JURORS, LET'S TAKE A
6 15-MINUTE RECESS UNTIL 11:30. PLEASE CONTINUE TO FOLLOW THE
7 ADMONITION. WE'LL SEE YOU BACK AT 11:30.

8 (RECESS TAKEN FROM 11:15 TO 11:30 A.M.)

9 THE COURT: OKAY. WE'RE BACK ON THE RECORD.

10 MR. OHLEMEYER.

11 MR. OHLEMEYER: JUST A FEW MORE QUESTIONS.

12 Q. DR. HENSLEY, I WANT TO MAKE SURE I'VE GOT SOME
13 TERMS STRAIGHT.

14 YOU MENTIONED EARLIER SOMETHING CALLED
15 "BRONCHOGENIC CARCINOMA OF THE LUNG."

16 A. YES, SIR.

17 Q. AND IS THAT A TYPE OF CANCER THAT STARTS -- WELL,
18 IS THAT A TYPE OF LUNG CANCER?

19 A. YES, SIR, IT IS.

20 Q. WHERE IN THE LUNG DOES THAT TYPE OF CANCER START?

21 A. WELL, IT STARTS IN THE LARGER AIRWAYS DERIVED
22 FROM THE TRACHEA OR WINDPIPE, AS THEY GO INTO THE LUNG.

23 Q. ARE THOSE KNOWN AS BRONCHUS?

24 A. YES, SIR. THE PLURAL IS BRONCHI, B-R-O-N-C-H-I.

25 THERE ARE TUBES THAT GO DOWN TO THE SIZE OF MAYBE
26 AROUND TWO MILLIMETERS. BRONCHOGENIC CARCINOMA ORIGINATE
27 FROM THEM.

28 Q. ARE THOSE THE TUBES, THE BRONCHI, THAT THE

JUDITH ANN OSSA, CSR NO. 2310

0034

1 BRONCHOSCOPY OR THE BRONCHOSCOPE IS INSERTED INTO WHEN A
2 BRONCHOSCOPY IS PERFORMED?

3 A. YES.

4 Q. IS SMALL CELL CARCINOMA OF THE LUNG -- STRIKE
5 THAT.

6 WHEN SMALL CELL CARCINOMA OF THE LUNG IS
7 DIAGNOSED, HOW OFTEN IS IT DIAGNOSED AS AN ENDOBRONCHIAL
8 LESION?

9 A. IT'S USUALLY AN ENDOBRONCHIAL LESION. PERHAPS,
10 IN FACT, ONE CAN SAY THAT SMALL CELL ANAPLASTIC CARCINOMA
11 ALWAYS ORIGINATES FROM THE MUCUS MEMBRANE OF THE BRONCHUS,
12 SO THAT IN FACT ALL ARE IN THAT LOCATION.

13 NOW, THEY MAY BE OVERLOOKED IF THEY'RE OUT TOO
14 FAR FOR THE BRONCHOSCOPE TO PENETRATE TO OR IF THE ORIGINAL
15 LESION IS VERY SMALL.

16 Q. BY THE WAY, WHEN WE TALK ABOUT SMALL CELL
17 CARCINOMA, DOES THAT REFER TO THE SIZE OF THE TUMOR?

18 A. NO, SIR. I REGRET TO SAY IT DOES NOT NECESSARILY
19 REFLECT THE SIZE OF EITHER THE TUMOR OR THE CELLS THAT
20 COMPOSE IT.

21 Q. SO IT CAN BE A MISNOMER IN TERMS OF SIZE?

22 A. IT IS A MISNOMER THAT IS USED FOR HISTORICAL
23 REASONS.

24 Q. AND THEN WOULD YOU DEFINE FOR ME OR EXPLAIN FOR
25 US WHAT THE PHRASE "CLINICAL PRESENTATION" MEANS.

26 A. WELL, "CLINICAL PRESENTATION" MEANS THE SIGNS OR
27 SYMPTOMS THAT BRING THE PATIENT TO THE ATTENTION OF A
28 PHYSICIAN.

JUDITH ANN OSSA, CSR NO. 2310

0035

1 Q. DO THEY INCLUDE THE WORKUP THAT'S SUBSEQUENTLY
2 DONE AFTER THE PATIENT SEES THE DOCTOR?

3 A. WELL, NOT STRICTLY SPEAKING. I SUPPOSE SOME
4 PEOPLE COULD USE THE TERM THAT WAY, BUT STRICTLY SPEAKING,
5 IT'S THE SIGNS AND SYMPTOMS THAT THE DOCTOR IS PRESENTED
6 WITH INITIALLY WHEN HE SEES THE PATIENT.

7 Q. DOCTOR, TAKING INTO ACCOUNT MS. HENLEY'S CLINICAL
8 PRESENTATION, THE X-RAYS, THE CT SCANS, THE RESULTS OF THE
9 BRONCHOSCOPY AND THE BIOPSY OBTAINED THROUGH THE
10 MEDIASTINOTOMY, IS THAT -- YOU'VE CONSIDERED ALL OF THAT IN
11 FORMING YOUR OPINION?

12 A. YES, SIR, I HAVE.

13 Q. IN YOUR EXPERIENCE AS A PATHOLOGIST, IS ALL OF
14 THAT INFORMATION COLLECTIVELY TYPICAL OF A PATIENT WHO HAS A
15 SMALL CELL CARCINOMA THAT BEGINS GROWING IN THE LUNG?

16 A. NO, SIR, IT IS NOT.

17 MR. OHLEMEYER: THANK YOU, DOCTOR. THOSE ARE ALL
18 THE QUESTIONS I HAVE.

19 THE COURT: MS. CHABER.

20

21 CROSS-EXAMINATION

22 BY MS. CHABER: Q. GOOD MORNING, DR. HENSLEY.

23 A. GOOD MORNING.

24 Q. YOU AND I HAVE MET ONCE BEFORE?

25 A. YES. NICE TO SEE YOU AGAIN.

26 Q. I TAKE IT YOUR EYES ARE BETTER?

27 A. MUCH BETTER.

28 Q. GOOD. GLAD TO HEAR THAT.

JUDITH ANN OSSA, CSR NO. 2310

0036

1 DR. HENSLEY, YOU WROTE NOTES IN THIS CASE, DIDN'T
2 YOU?

3 A. YES.

4 Q. NOW, LET ME UNDERSTAND THE ORIGIN OF YOUR GETTING
5 INVOLVED IN THIS CASE.

6 YOU HAVE DONE WORK IN THE PAST ON BEHALF OF
7 CIGARETTE COMPANIES IN THEIR DEFENSE OF CASES; CORRECT?

8 A. WELL, MORE PRECISELY STATED, I'M CONSULTED BY
9 SHOOK, HARDY & BACON, WHICH DOES REPRESENT SOME CIGARETTE
10 COMPANIES, BUT I DON'T EVEN KNOW WHICH ONES THEY ARE.

11 Q. YOU UNDERSTAND, THOUGH, WHEN SHOOK, HARDY & BACON
12 IS CONTACTING YOU, THAT THEY ARE CONTACTING YOU WITH RESPECT
13 TO THEIR DEFENSE IN A CASE WHERE AN INDIVIDUAL OR
14 INDIVIDUALS ARE ALLEGING THAT THEY HAVE BEEN HARMED BY
15 CIGARETTE SMOKE?

16 A. YES, MA'AM.

17 Q. AND YOUR INVOLVEMENT WITH SHOOK, HARDY & BACON,
18 THIS IS NOT THE FIRST TIME THAT YOU WERE INVOLVED WITH THEM;
19 CORRECT?

20 A. NO. IT'S THE FIRST TIME I'VE TESTIFIED FOR THEM,

21 BUT I HAVE BEEN INVOLVED WITH THEM PREVIOUSLY.
22 Q. AND YOU'VE CONSULTED ON CASES BEFORE WITH THEM?
23 A. YES, MA'AM.
24 Q. AND YOU HAVE BEEN DEPOSED, WHERE YOU'RE ASKED
25 QUESTIONS OUTSIDE OF THE COURTROOM UNDER OATH; CORRECT?
26 A. YES.
27 Q. AND IN FACT, RECENTLY, YOU'VE BEEN DEPOSED IN A
28 CASE CALLED ENGLE, E-N-G-L-E?

JUDITH ANN OSSA, CSR NO. 2310

0037

1 A. YES.
2 Q. AND THAT'S A CLASS ACTION --
3 MR. OHLEMEYER: EXCUSE ME, YOUR HONOR. I OBJECT
4 TO THIS AS IMPROPER CROSS-EXAMINATION.
5 MS. CHABER: IT GOES TO --
6 THE COURT: THE DETAILS OF THE CASE ARE NOT
7 IMPORTANT.
8 MS. CHABER: Q. YOU UNDERSTAND THAT YOUR ROLE
9 IN ENGLE RELATES TO MANY PEOPLE ALLEGING INJURY FROM
10 CIGARETTE SMOKE; CORRECT?
11 MR. OHLEMEYER: SAME OBJECTION.
12 THE COURT: THAT IS THE SAME QUESTION I JUST
13 SUSTAINED AN OBJECTION TO.
14 MS. CHABER: I'M JUST DISTINGUISHING THAT IT'S
15 NOT AN INDIVIDUAL CASE.
16 THE COURT: DON'T ARGUE. I HAVE SUSTAINED THE
17 OBJECTION TWICE NOW. JUST DON'T ASK THE SAME QUESTION
18 AGAIN.
19 YOU CAN ASK ANOTHER ONE.
20 MS. CHABER: Q. DOCTOR, YOU HAVE DONE WORK FOR
21 SHOOK, HARDY & BACON IN CASES WHERE PEOPLE HAVE ALLEGED
22 BUERGER'S DISEASE; CORRECT?
23 A. I DON'T KNOW.
24 NO, NOT DIRECTLY. WE HAVE DISCUSSED BUERGER'S
25 DISEASE, BUT I'VE NEVER BEEN PRESENTED WITH, SO FAR AS I
26 KNOW, SPECIFIC ALLEGATIONS OF BUERGER'S DISEASE.
27 Q. YOU UNDERSTAND THAT THAT'S ONE OF THE ALLEGATIONS
28 IN THIS ENGLE CASE, DON'T YOU?

JUDITH ANN OSSA, CSR NO. 2310

0038

1 MR. OHLEMEYER: YOUR HONOR --
2 THE COURT: SUSTAINED.
3 THE WITNESS: I'M NOT SURE.
4 THE COURT: SUSTAINED.
5 MS. CHABER: Q. NOW, YOUR WRITINGS, NOTES IN
6 THIS CASE, THAT'S NOT UNUSUAL FOR A DOCTOR TO DO, IS IT?
7 A. NOT AT ALL.
8 Q. IN FACT, WHEN YOU LOOK AT PATHOLOGY MATERIALS,
9 YOU PROBABLY TAKE NOTES REGULARLY; CORRECT?
10 A. DEPENDING ON THE PURPOSE, YES.
11 Q. AND IS IT FAIR TO SAY THAT, GENERALLY, YOU WRITE
12 UP SOME KIND OF A REPORT?
13 A. WELL, ACTUALLY, NO. IN THE CASE OF CONSULTATIONS
14 OF THIS TYPE, WHAT I SIMPLY DO IS WRITE A SERIES OF NOTES
15 WHICH ARE MEANT TO JOG MY MEMORY ABOUT SPECIFIC SLIDES, AND
16 I WILL LIST A DIAGNOSIS, BUT I DON'T ACTUALLY WRITE A
17 REPORT.
18 Q. YOU'RE RETIRED NOW; CORRECT?
19 A. YES, MA'AM.
20 Q. WHEN YOU WERE PRACTICING, AS A PRACTICING
21 PATHOLOGIST, IT WAS YOUR REGULAR CUSTOM TO WRITE NOTES AND
22 WRITE REPORTS; CORRECT?
23 A. WELL, NOT PRECISELY. WHEN I WAS DOING DIAGNOSTIC

24 WORK AT THE UNIVERSITY, I WAS WORKING WITH GRADUATE STUDENTS
25 WHO WERE STUDYING PATHOLOGY, PHYSICIANS WHO WOULD SIT DOWN
26 WITH ME AT THE MICROSCOPE AND DISCUSS THE CASES.
27 AND WE WOULD ARRIVE AT AN OPINION. AND THEY
28 WOULD MAKE NOTES, AND THEY WOULD BE RESPONSIBLE FOR
JUDITH ANN OSSA, CSR NO. 2310

0039

1 DICTATING THE REPORT, WHICH I SUBSEQUENTLY WOULD READ AND
2 SIGN.
3 BUT I DIDN'T ACTUALLY DO THAT OVER THE PAST 20
4 YEARS, BECAUSE I HAD OTHERS TO DO IT FOR ME.
5 Q. BUT SOMEBODY WAS WRITING A REPORT?
6 A. ABSOLUTELY.
7 Q. AND YOU IN FACT WOULD REVIEW IT AND HAVE TO SIGN
8 OFF ON IT; CORRECT?
9 A. ABSOLUTELY.
10 Q. AND IN THIS CASE, WHEN YOU WERE ASKED TO BE
11 INVOLVED IN MS. HENLEY'S CASE, YOU DID NOT PREPARE A REPORT;
12 CORRECT?
13 A. YES. I'VE ALREADY SAID THAT, I BELIEVE.
14 Q. NO ONE ELSE PREPARED A REPORT FOR YOU TO REVIEW
15 AND SIGN, DID THEY?
16 A. OH, NO.
17 Q. AND WHEN YOU FIRST WERE ASKED TO BE INVOLVED IN
18 MS. HENLEY'S CASE, THREE LAWYERS CAME TO MEET WITH YOU?
19 A. WELL, I DON'T REALLY RECALL HOW MANY THERE WERE.
20 I RECALL THAT SOMETIME IN THE AUTUMN OF LAST YEAR, I MET
21 WITH ONE OR MORE PEOPLE FROM THE FIRM WHO BROUGHT ME THOSE
22 SLIDES.
23 Q. YES.
24 IN FACT, YOU WEREN'T SENT THE SLIDES. THE
25 LAWYERS ACTUALLY CAME AND BROUGHT YOU THE SLIDES; RIGHT?
26 A. TO MY OFFICE.
27 Q. AND YOU LOOKED AT THE PATHOLOGY SLIDES WITH THE
28 LAWYERS; CORRECT?

JUDITH ANN OSSA, CSR NO. 2310

0040

1 A. WITH THE LAWYERS PRESENT.
2 Q. AND WHEN YOU'VE BEEN INVOLVED IN THE PAST WITH
3 SHOOK, HARDY & BACON, THERE'S A PARTICULAR LAWYER THAT IS
4 RESPONSIBLE FOR DEALING WITH YOU; CORRECT?
5 A. NOT A SPECIFIC INDIVIDUAL.
6 Q. MR. SIRRIDGE ISN'T THE INDIVIDUAL WHO DEALS WITH
7 YOU?
8 A. NO, MA'AM.
9 Q. HE IS SOMEONE WHO HAS DEALT WITH YOU?
10 A. YES, BUT HE'S NEVER BROUGHT SLIDES TO MY OFFICE,
11 AND THAT'S THE WAY I CONSTRUED YOUR QUESTION.
12 Q. NONE OF THE LAWYERS THAT ARE SITTING HERE AT
13 COUNSEL TABLE ARE THE ONES THAT BROUGHT THE SLIDES TO YOU,
14 ARE THEY?
15 A. NONE OF THEM, NO.
16 Q. NOW, IN ADDITION TO REVIEWING THE MEDICAL RECORDS
17 IN THIS CASE AND LOOKING AT THE SLIDES, YOU ALSO REVIEWED
18 SOME REPORTS THAT WERE PREPARED IN THIS CASE BY OTHER PEOPLE
19 INVOLVED; CORRECT?
20 A. FROM THE MEDICAL RECORDS.
21 Q. WERE YOU GIVEN A 14-PAGE REPORT PREPARED BY DR.
22 HORN TO REVIEW?
23 A. NO.
24 Q. WERE YOU GIVEN A FOUR-PAGE REPORT PREPARED BY DR.
25 HAMMAR TO REVIEW?
26 A. NO.

27 Q. WERE YOU GIVEN A 30-PAGE REPORT BY DR. FEINGOLD
28 TO REVIEW?

JUDITH ANN OSSA, CSR NO. 2310

0041

1 A. NO.

2 Q. NOW, YOU'D AGREE, WOULD YOU NOT, SIR, THAT IN
3 REVIEWING THE MEDICAL RECORDS, THE CONSENSUS OF MS. HENLEY'S
4 TREATING PHYSICIANS WAS THAT SHE HAD SMALL CELL CARCINOMA OF
5 THE LUNG?

6 A. YES.

7 Q. AND YOU WOULD AGREE THAT THE PEOPLE WHO ARE
8 CHARGED WITH HER TREATMENT AND HER CARE AT THE PRESENT TIME
9 HAVE DIAGNOSED SMALL CELL CARCINOMA OF THE LUNG?

10 A. WELL, I'M NOT SURE OF THAT FACT. I HAVE LOOKED
11 AT THE MEDICAL RECORDS UP TO A POINT, AND I DON'T KNOW TO
12 WHOM YOU'RE REFERRING.

13 Q. YOU LOOKED AT DR. RAUL MENA'S RECORDS, DIDN'T
14 YOU?

15 A. I DON'T RECALL THE NAME, BUT I MAY HAVE REVIEWED
16 THE RECORDS AND JUST MAY HAVE A FAULTY MEMORY.

17 Q. AND HAVE YOU CALLED ANY OF HER TREATING
18 PHYSICIANS TO TELL THEM THAT THEIR DIAGNOSIS IS INCORRECT?

19 A. NO.

20 Q. HAVE YOU -- NOW, LET ME UNDERSTAND --
21 MR. OHLEMEYER: EXCUSE ME, YOUR HONOR.
22 THE WITNESS: MAY I ADD SOMETHING TO THAT?
23 MS. CHABER: Q. SURE.

24 A. WE'RE TALKING ABOUT PROFESSIONAL OPINIONS. WE'RE
25 NOT TALKING ABOUT WHAT IS RIGHT AND WHAT IS WRONG.

26 I WOULDN'T PRESUME TO CALL THOSE PHYSICIANS AND
27 TELL THEM, "HEY, YOU'RE WRONG AND I'M RIGHT." I MIGHT TALK
28 WITH THEM AND DISCUSS THE REASONS FOR MY OPINION, BUT

JUDITH ANN OSSA, CSR NO. 2310

0042

1 THERE'S NO REASON THAT I WOULD PICK UP THE TELEPHONE AND
2 CALL SOMEBODY AND SAY "YOU'RE WRONG" IN A CASE LIKE THIS.

3 Q. YOU'D ASSUME IT WOULD BE IMPORTANT FOR THE
4 TREATING PHYSICIANS TO KNOW THAT THEY HAD THE CORRECT
5 DIAGNOSIS, DON'T YOU?

6 A. NO. AT THIS POINT, IT DOESN'T MAKE MUCH
7 DIFFERENCE. THE CHEMOTHERAPY AND THE RADIATION USED FOR THE
8 TWO NEOPLASMS IN QUESTION HAPPEN TO BE THE SAME.

9 THAT MAKES IT UNIMPORTANT TO CLARIFY IT WITH
10 RESPECT TO THE TREATMENT IN QUESTION.

11 Q. NOW, WITH RESPECT TO DR. MENA, THE PERSON WHO
12 ADMINISTERED TREATMENT TO HER, WERE YOU PROVIDED WITH HIS
13 TESTIMONY AND HIS STATEMENT THAT IF HE THOUGHT THIS WAS A
14 THYMIC CANCER, HE WOULD HAVE WANTED TO DO LITERATURE REVIEWS
15 WITH RESPECT TO THE CORRECT CHEMOTHERAPY AND RADIATION?

16 MR. OHLEMEYER: YOUR HONOR, I OBJECT TO THE
17 QUESTION AS BEING ARGUMENTATIVE.

18 THE COURT: WELL, IS YOUR OBJECTION THAT IT
19 MISCHARACTERIZES THE EVIDENCE?

20 MR. OHLEMEYER: FIRST OF ALL --

21 THE COURT: IT'S NOT ARGUMENTATIVE.

22 MR. OHLEMEYER: FIRST OF ALL, THE WITNESS --I
23 DON'T WANT TO SPEAK OUT OF TURN. YOU HAVE INVOKED THE
24 RULE.

25 THE WITNESS COULDN'T HAVE READ DR. MENA'S TRIAL
26 TESTIMONY, SO IT'S AN ARGUMENTATIVE QUESTION.

27 THE COURT: ALL RIGHT. I WILL SUSTAIN.

28 MS. CHABER: Q. DR. HENSLEY, YOU HAVE NO

JUDITH ANN OSSA, CSR NO. 2310

0043

1 CRITICISMS OF THE CARE OR TREATMENT THAT MS. HENLEY
2 RECEIVED; CORRECT?

3 A. NO.

4 Q. AND YOU HAVE NO CRITICISMS THAT HER DOCTORS WHO
5 WERE MAKING DIAGNOSES ABOUT HER WERE INCOMPETENT?

6 A. OF COURSE NOT.

7 Q. AND I THINK YOU SAID THAT IF IT'S NOT A LUNG
8 CANCER, IT'S A THYMIC CANCER.

9 IS THAT WHAT YOUR OPINION IS, SIR?

10 A. NO. MORE PRECISELY, MY OPINION IS THAT THE
11 WEIGHT OF EVIDENCE INDICATES THIS IS MORE LIKELY TO BE A
12 CANCER ORIGINATING FROM THE THYMUS GLAND THAN FROM THE LUNG.

13 Q. AND THAT WOULD BE A THYMIC CANCER; CORRECT?

14 A. I BELIEVE I SAID THAT.

15 Q. SO IN YOUR DIFFERENTIAL DIAGNOSIS, THE NO. 1
16 THING YOU'D CONSIDER IS THYMIC CANCER; CORRECT?

17 A. IN THIS PARTICULAR CASE.

18 Q. AND YOU UNDERSTAND, DON'T YOU, SIR, THAT A SMALL
19 CELL TYPE OF THYMIC CANCER IS EXCEEDINGLY RARE?

20 A. OF COURSE.

21 Q. AND YOU'VE NEVER DIAGNOSED A PRIMARY THYMIC SMALL
22 CELL CANCER, HAVE YOU?

23 A. NO.

24 Q. IN FACT -- STRIKE THAT.

25 YOU'D AGREE THAT A DOCTOR MAKING A DIAGNOSIS,
26 BEFORE THEY MAKE THE FINAL JUDGMENT CALL, THEY NEED TO
27 ADDRESS THE QUESTION OF PROBABILITIES?

28 A. IF THERE ISN'T ANY ALTERNATIVE, PROBABILITIES MAY
JUDITH ANN OSSA, CSR NO. 2310

0044

1 BE REASONABLY CONSIDERED IN A DIAGNOSIS.

2 BUT OF COURSE, AS I SAID PREVIOUSLY, IN MEDICINE,
3 WE DON'T LIKE TO USE HOW PROBABLE IT IS SOMEBODY HAS CANCER,
4 BUT TO LOOK FOR DEFINITE EVIDENCE.

5 PROBABILITIES ARE NOT TERRIBLY RELIABLE, FROM MY
6 STANDPOINT.

7 Q. DOCTOR, DO YOU RECALL BEING DEPOSED BY ME?

8 A. YES.

9 Q. AND DO YOU RECALL, IN YOUR DEPOSITION, SAYING
10 THAT BEFORE A DOCTOR MAKES A FINAL JUDGMENT CALL, HE HAS TO
11 TAKE THE PROBABILITIES INTO CONSIDERATION?

12 A. I DON'T RECOGNIZE THE CONTEXT.

13 WOULD YOU MIND SHOWING ME? I'M SURE I SAID THAT,
14 IF YOU SAY IT, BUT I JUST DON'T RECOGNIZE THE CONTEXT.

15 Q. I'LL FIND IT IN A MINUTE.

16 DOCTOR, DO YOU RECALL BEING ASKED THE QUESTION:
17 WHAT ARE THE FEATURES OF ANAPLASTIC CARCINOMA THAT ARE
18 CONSISTENT WITH A THYMIC ORIGIN, GENERALLY?

19 A. YES.

20 Q. AND YOU INDICATED THAT THERE ARE NO MICROSCOPIC
21 FEATURES THAT WOULD DISTINGUISH A SMALL CELL ANAPLASTIC
22 CARCINOMA ORIGINATING IN ANY ONE PLACE FROM ANOTHER PLACE?
23 DO YOU RECALL SAYING THAT?

24 A. YES, I SAID THAT.

25 Q. AND DO YOU RECALL SAYING THAT THEY ALL LOOK THE
26 SAME, THAT THEY'RE ALL IDENTICAL?

27 A. I DID SAY THAT.

28 Q. AND YOU RECALL SAYING THAT THE DIAGNOSIS THEN HAS
JUDITH ANN OSSA, CSR NO. 2310

0045

1 TO BE MADE LOOKING AT THE GROSS ANATOMICAL FEATURES;
2 CORRECT?

3 A. YES.
4 Q. AND COMPARING ORGANS TO SEE WHICH ARE MOST LIKELY
5 TO BE THE SITE OF ORIGIN OF A PARTICULAR TUMOR IN QUESTION?
6 A. YES.
7 Q. AND THEN TO CAREFULLY ADDRESS THE QUESTION OF
8 PROBABILITIES BEFORE YOU MAKE A FINAL JUDGMENT CALL. DO YOU
9 RECALL SAYING THAT?
10 A. I THINK THERE'S A TYPO THERE. I BELIEVE WHAT I
11 SAID IS "PROBABILITY," NOT "PROBABILITIES."
12 IF I DIDN'T CATCH THAT IN A CORRECTION, I SHOULD
13 HAVE.
14 Q. YOU DID MAKE CORRECTIONS TO YOUR DEPOSITION,
15 DIDN'T YOU?
16 A. YES, BUT I DID NOT MEAN TO IMPLY THAT WE'RE
17 TALKING ABOUT STATISTICAL PROBABILITIES.
18 I WAS TRYING TO IMPLY THAT WE'RE TALKING ABOUT
19 WHAT IS MORE PROBABLE IN THE DIFFERENTIAL DIAGNOSIS. IS IT
20 MORE LIKELY THAT A IS CORRECT OR B IS CORRECT.
21 Q. DID YOU SEE ANYWHERE IN MS. HENLEY'S MEDICAL
22 RECORDS THAT ONE SINGLE ONE OF HER DOCTORS WHO WERE INVOLVED
23 IN THE DIAGNOSIS, TREATMENT OR CARE OF HER HAD, AS PART OF
24 THEIR DIFFERENTIAL DIAGNOSIS, A THYMIC SMALL CELL CANCER?
25 A. NO.
26 Q. AND SIR, YOU WOULD AGREE, WOULD YOU NOT, THAT ON
27 THE PROBABILITY SCALE OF LUNG CANCER VERSUS THYMIC CANCER,
28 THAT THERE'S LESS THAN A .15 PERCENT PROBABILITY OF A SMALL

JUDITH ANN OSSA, CSR NO. 2310
0046

1 CELL CANCER BEING THYMIC VERSUS A LUNG CANCER?
2 A. AS I EXPLAINED, I DON'T THINK THAT'S RELEVANT.
3 THE PROBABILITY THAT I WAS TALKING ABOUT IS WHETHER IT'S
4 MORE PROBABLE THAT THIS PARTICULAR TUMOR ORIGINATED IN THE
5 LUNG THAN IN THE THYMUS.
6 AND I TRIED TO SETTLE THAT ISSUE NOT BASED ON THE
7 STATISTICAL ODDS BUT BY THE ANATOMICAL EVIDENCE AVAILABLE TO
8 ME.
9 Q. LET'S LOOK AT THE LIKELIHOOD, DOCTOR, OF A THYMIC
10 CANCER. LET'S TALK FOR A MOMENT, EVEN THOUGH THAT'S NOT
11 WHAT YOU MEANT BY THAT, ABOUT PROBABILITIES.
12 DO YOU KNOW HOW MANY LUNG CANCERS THERE ARE IN
13 ANY GIVEN YEAR IN THE UNITED STATES?
14 A. OH, I KNOW THAT FROM TIME TO TIME WHEN I LOOK IT
15 UP, BUT I CERTAINLY DON'T REMEMBER IT.
16 I WOULD CERTAINLY AGREE WITH YOU THAT THE RATIO
17 OF LUNG CANCER TO THYMIC CANCER IS SKEWED VERY, VERY HEAVILY
18 IN FAVOR OF LUNG CANCER.
19 Q. AND IN FACT, IN 1999, THE PROJECTIONS -- YOU KNOW
20 WHAT THE SEER DATA IS, DON'T YOU?
21 A. YES.
22 Q. AND THE SEER DATA IS DATA THAT IS COLLECTED WITH
23 RESPECT TO THE ORIGINS, THE SITES OF CANCERS?
24 A. YES, BUT YOU HAVE TO REMEMBER THAT THESE DATA ARE
25 DERIVED FROM RECORDS AND THE VALIDITY OF THE DATA MIGHT BE
26 SLIGHTLY IN QUESTION.
27 NEVERTHELESS, I'M NOT GOING TO DISPUTE IN ANY WAY
28 THE VALIDITY. I'M JUST POINTING OUT THAT THE NUMBERS GIVEN

JUDITH ANN OSSA, CSR NO. 2310
0047

1 ARE NOT ABSOLUTELY CORRECT, BUT THEY'RE REASONABLE
2 ESTIMATES.
3 Q. AND SO 180,000 CANCERS -- EXCUSE ME -- 180,000
4 CANCER DEATHS ARE NOTED ORIGINATING IN THE LUNG.
5 YOU WOULDN'T DISAGREE WITH THOSE NUMBERS?

6 A. NO.
7 Q. AND OF THE TYPES OF LUNG CANCER, ABOUT 20 TO 25
8 PERCENT OF LUNG CANCER TYPE ARE SMALL CELL?
9 A. APPROXIMATELY.
10 Q. AND DO YOU KNOW HOW MANY DEATHS THERE ARE FROM
11 THYMIC CANCERS OR THE INCIDENCE OF THYMIC CANCERS?
12 A. I HAVEN'T LOOKED UP THAT DATA, BUT IT MUST BE A
13 VERY SMALL NUMBER, BECAUSE THOSE CANCERS ARE RARE.
14 Q. LESS THAN 100?
15 A. WELL, WHEN YOU TALK ABOUT THESE NUMBERS, YOU HAVE
16 TO REALIZE THAT -- LESS THAN 100? WELL, THAT'S A NUMBER OF
17 CASES THAT WERE RECOGNIZED, BUT THEN HOW MANY WERE NOT
18 RECOGNIZED? SO THAT'S AN ESTIMATE. IT'S REASONABLE.
19 AND I GUESS I COULD AGREE TO TALK ABOUT IT, BUT I
20 COULDN'T SAY IT'S 100 PERCENT ACCURATE.
21 Q. AND THE NUMBER OF THYMIC CANCERS, HOWEVER SMALL,
22 THAT IS EVEN SMALLER IF YOU LOOK AT THE CELL TYPE, SMALL
23 CELL CANCER; CORRECT?
24 A. ABSOLUTELY.
25 Q. SO WE'RE TALKING ABOUT A RARE CELL TYPE OF A RARE
26 DISEASE?
27 A. WHICH, TO ME, HAS LITTLE TO DO WITH MS. HENLEY.
28 I DON'T WANT TO MAKE A DIAGNOSIS ON HER BASED ON ODDS. I'D
JUDITH ANN OSSA, CSR NO. 2310

0048

1 RATHER DO IT ON THE BASIS OF THE ANATOMY OF MS. HENLEY.
2 Q. AND IN YOUR OPINION, SINCE MS. HENLEY WOULD BE
3 CLASSIFIED AS A LUNG CANCER FOR SEER DATA, THAT WOULD BE A
4 MISCLASSIFICATION; CORRECT?
5 A. SURE. AND THERE ARE MANY MISCLASSIFICATIONS IN
6 ANY LARGE SERIES.
7 Q. SO IT WOULD BE REALLY IMPORTANT TO HAVE THE
8 DIAGNOSIS BE CORRECT SO THAT THE STATISTICS THAT ARE BEING
9 KEPT ARE ACCURATE, WOULDN'T IT?
10 A. WELL, MA'AM, I'VE ALREADY SAID, I'M NOT EXACTLY
11 SITTING HERE SAYING THAT I'M AN ARBITER OF WHAT IS EXACTLY
12 RIGHT AND EXACTLY WRONG. THE BEST I CAN DO FOR ANYBODY IS
13 TO GIVE THEM MY BEST PROFESSIONAL OPINION.
14 I HAVE MY OPINION, WHICH DIFFERS FROM THE TESTING
15 FIGURES AND WHAT IS IN THAT SERIES, BUT I DON'T FEEL
16 IMPELLED TO GO OUT AND TRY TO CORRECT THE RECORD.
17 Q. AND YOU KNOW WHO DR. HAMMAR IS, DON'T YOU?
18 YOU'VE HEARD OF HIM?
19 A. ONLY VERY SUPERFICIALLY.
20 Q. OKAY. YOU'RE FAMILIAR WITH THE TEXTBOOKS THAT
21 HE'S WRITTEN?
22 A. WELL, I WOULDN'T SAY I'M CONVERSANT WITH HIS
23 TEXTBOOKS. I KNOW HE'S WRITTEN.
24 Q. AND IT WAS DR. HAMMAR'S OPINION IN THIS COURTROOM
25 THAT THE TUMOR WAS NOT GROWING INTO THE LUNG BUT RATHER
26 EXTENDING IN THE OTHER DIRECTION?
27 MR. OHLEMEYER: YOUR HONOR. IT'S ARGUMENTATIVE.
28 THE WITNESS: I WOULD --
JUDITH ANN OSSA, CSR NO. 2310

0049

1 THE COURT: JUST A SECOND. THERE IS AN
2 OBJECTION.
3 MR. OHLEMEYER: OBJECTION. IT'S ARGUMENTATIVE.
4 THE COURT: IT'S AN INAPPROPRIATE FORM FOR A
5 QUESTION.
6 SUSTAINED.
7 MS. CHABER: Q. I WANT YOU TO ASSUME THAT
8 THERE'S BEEN TESTIMONY IN THIS COURTROOM THAT, RATHER THAN

9 WHAT I BELIEVE YOU SAID THE TUMOR WAS -- LET ME FIND WHAT
10 YOU SAID.
11 THE COURT: WHILE YOU ARE LOOKING FOR THAT, LET
12 ME ASK YOU A SCHEDULING ISSUE, MS. CHABER. IF WE STAY FOR A
13 FEW MINUTES, ARE WE LIKELY TO FINISH WITH THE DOCTOR BEFORE
14 LUNCH OR NOT?
15 MS. CHABER: IF WE STAYED FOR MAYBE 15 MINUTES,
16 BUT NOT JUST ONE OR TWO, I COULD PROBABLY DO IT.
17 THE COURT: LET ME ASK THE JURY: ARE THERE ANY
18 OF YOU THAT WOULD BE INCONVENIENCED IF WE WENT FOR ABOUT 15
19 MORE MINUTES? WOULD THAT INTERFERE WITH ANYBODY'S LUNCH
20 PLANS? TATSUO OR JUDITH, EITHER OF YOU? YOU'RE BOTH OKAY
21 WITH THAT?
22 ALL RIGHT. EVERYBODY HAS INDICATED THEY ARE
23 OKAY. WHY DON'T WE PUSH FORWARD ON THIS.
24 AND AGAIN, I MIGHT HAVE THE JURY TAKE A LITTLE
25 SHORTER OF A LUNCH TODAY, TO MAKE UP FOR SOME OF THE TIME
26 THEY LOST THIS MORNING.
27 MS. CHABER: Q. LET ME ASK YOU ANOTHER
28 QUESTION. I BELIEVE I HEARD THIS CORRECTLY ON DIRECT, BUT I
JUDITH ANN OSSA, CSR NO. 2310

0050

1 WANT TO MAKE SURE.
2 DID YOU SAY THAT YOU DO NOT KNOW HOW A THYMIC
3 CANCER SPREADS?
4 A. NO, I DON'T THINK I SAID THAT.
5 Q. OKAY.
6 A. I CERTAINLY DIDN'T INTEND TO.
7 Q. DO YOU KNOW HOW A THYMIC CANCER SPREADS?
8 A. WELL, THAT IS A VERY GENERAL QUESTION. AND YOU
9 HAVE TO SAY THAT THE LOW-GRADE THYMIC CANCERS LOCALLY INVADE
10 THE MEDIASTINAL STRUCTURES, INCLUDING THE HEART AND OFTEN
11 THE LUNG, AND THEY FREQUENTLY CAUSE DEATH FROM THIS LOCAL
12 DESTRUCTION.
13 THE HIGH-GRADE CANCERS, ON THE OTHER HAND, WHICH
14 WOULD INCLUDE SMALL CELL ANAPLASTIC, WILL METASTASIZE BY THE
15 LYMPHATICS IN THE BLOODSTREAM, AND REACH OTHER ORGANS AND
16 CAUSE MISCHIEF THERE.
17 Q. SO IN ORDER FOR A THYMIC CANCER TO GET TO THE
18 BRONCHI AND TO OTHER PARTS OF THE MEDIASTINUM AND BE A SMALL
19 CELL, IT WOULD HAVE HAD TO GO TO LYMPH GLANDS?
20 A. NO, MA'AM. NO. YOU SEE, THE THYMUS GLAND OF THE
21 HUMAN BEING LIES BASICALLY IN THE RETROSTERNAL SPACE.
22 FREQUENTLY, IN PEOPLE, THERE ARE TWO TONGUES OF TISSUE THAT
23 GO TO EITHER SIDE AS YOU GO DOWN THE ORGAN, AND FREQUENTLY
24 THEY LIE AGAINST THE BRONCHUS IN THE MEDIASTINUM.
25 SO THAT THYMOMAS ORIGINATING FROM THE PORTION OF
26 THE THYMUS OR THYMIC REMNANT THAT IS NORMALLY IN ANATOMICAL
27 RELATION TO THE BRONCHUS, IT'S ALREADY THERE.
28 Q. THIS ISN'T A THYMOMA, DOCTOR. A THYMOMA IS A
JUDITH ANN OSSA, CSR NO. 2310

0051

1 BENIGN DISEASE, ISN'T IT?
2 A. NO. MANY PEOPLE HAVE USED THE TERM "THYMOMA" TO
3 INDICATE A BENIGN TUMOR OF THE THYMUS.
4 BUT AS I'M USING THE TERM HERE TODAY, I'M USING
5 THE TERM "THYMOMA" COLLECTIVELY TO INDICATE ANY NEOPLASM OF
6 THE THYMUS, WHETHER BENIGN OR MALIGNANT.
7 Q. YOU'D AGREE THAT MS. HENLEY DOESN'T HAVE A BENIGN
8 DISEASE?
9 A. ABSOLUTELY.
10 Q. AND YOU'D AGREE THAT MS. HENLEY HAS A DISEASE
11 THAT -- WHAT WAS THE DIFFERENTIATION YOU GAVE BETWEEN -- YOU

12 DIDN'T SAY EXTENSIVE, DID YOU?
13 A. I SAID HIGH-GRADE AND LOW-GRADE.
14 Q. HIGH-GRADE AND LOW-GRADE.
15 AND THIS WOULD BE HIGH-GRADE, WHAT MS. HENLEY
16 HAS; CORRECT?
17 A. ABSOLUTELY.
18 Q. AND HIGH-GRADE THYMUS OR THYMIC CANCERS SPREAD
19 THROUGH THE LYMPH NODES; CORRECT?
20 A. AS WELL AS LOCALLY IN THE MEDIASTINUM.
21 BUT BEFORE THEY SPREAD TO THE LYMPH NODES,
22 THEY SPREAD THROUGH THE THYMUS GLAND. IT'S USUALLY
23 POSSIBLE -- IT'S USUALLY POSSIBLE IN EXAMINING THYMIC
24 CANCERS TO RECOGNIZE REMNANTS OF THYMUS, AND SOMETIMES IN
25 TRANSITIONS FROM THE NORMAL STRUCTURES TO CANCER.
26 Q. NOW, DR. HENSLEY, YOU DIDN'T FIND PIECES OF
27 THYMIC GLAND IN MS. HENLEY'S BIOPSY?
28 A. I DON'T KNOW. AS I INDICATED EARLIER, I BELIEVE
JUDITH ANN OSSA, CSR NO. 2310

0052

1 IF YOU REVIEW WHAT I SAID THIS MORNING, YOU'LL FIND THAT I
2 SAID THAT WE FOUND FAT TISSUE, AND THAT THE NORMAL HUMAN
3 INVOLUTED THYMUS CONTAINS FAT TISSUE. IT COULD HAVE BEEN
4 THYMUS TISSUE.
5 BUT IT MIGHT HAVE BEEN ADIPOSE TISSUE FROM THE
6 MEDIASTINUM ITSELF, AND I CAN'T REALLY BE SURE WHICH.
7 Q. AND THE REST OF IT WAS TUMOR TISSUE; CORRECT?
8 A. YES, MA'AM.
9 Q. AND TUMOR TISSUE CAN OVERCOME LYMPH NODES,
10 PARTICULARLY IF YOU HAVE -- IF YOU'VE TAKEN A SMALL, LITTLE
11 BIOPSY?
12 A. I DON'T UNDERSTAND THE QUESTION.
13 Q. TUMOR, WHEN IT GOES TO THE LYMPH NODES, CAN
14 DESTROY A LYMPH NODE, CAN'T IT?
15 A. YES.
16 Q. AND IF YOU'VE TAKEN A PIECE OF A BIOPSY AND
17 YOU'RE LOOKING THROUGH THE MICROSCOPE AND YOU'RE LOOKING AT
18 TUMOR, YOU DON'T KNOW WHAT THAT WAS BEFORE IT WAS TUMOR?
19 A. NO, THAT'S FALSE. AS A MATTER OF FACT, LYMPH
20 NODES OF THE MEDIASTINUM DO NOT NORMALLY CONTAIN FAT CELLS.
21 AND CONSEQUENTLY, LOOKING AT THE BIOPSY AND
22 SEEING THE FAT CELLS, I CAN CONFIDENTLY SAY THAT THAT WAS
23 NOT LYMPH NODE.
24 Q. THE SMALL PART OF IT THAT WAS A FAT; CORRECT?
25 A. THAT PART OF IT WHICH WAS FAT.
26 Q. AND WITH RESPECT TO THE DIAGNOSIS OF A PRIMARY
27 THYMIC CARCINOMA, YOU'RE FAMILIAR WITH AN ARTICLE BY SAUL
28 SUSTER, S-U-S-T-E-R, AND CESAR, C-E-S-A-R, MORAN?
JUDITH ANN OSSA, CSR NO. 2310

0053

1 A. YES, MA'AM.
2 Q. AND IT'S TRUE, IS IT NOT, THAT THEY SAY THAT THE
3 DIAGNOSIS OF THYMIC CARCINOMA MUST ALWAYS BE ONE OF
4 EXCLUSION?
5 A. YES. I FULLY AGREE WITH THAT STATEMENT.
6 Q. AND SO THAT I DON'T MISREAD --
7 A. I WOULD LIKE TO ADD SOMETHING, IF YOU DON'T
8 MIND.
9 IN THAT SAME ARTICLE, THEY SAY THAT IT MIGHT BE
10 NECESSARY TO --
11 Q. DOCTOR.
12 A. YES.
13 Q. I DON'T THINK THERE IS A QUESTION PENDING.
14 A. OH. I'M SORRY.

15 MS. CHABER: I'M SURE MR. OHLEMEYER WILL BE
16 HAPPY TO ASK YOU WHATEVER QUESTIONS HE WANTS TO.
17 I'D LIKE TO HAVE MARKED AS PLAINTIFF'S NEXT IN
18 ORDER AN ARTICLE TITLED "THYMIC CARCINOMA."
19 THE CLERK: PLAINTIFF'S EXHIBIT 78.
20 (DOCUMENT MORE PARTICULARLY
21 DESCRIBED IN THE INDEX MARKED
22 FOR IDENTIFICATION PLAINTIFF'S
23 EXHIBIT # 78)
24 THE CLERK: DO YOU HAVE A COPY FOR THE JUDGE?
25 MS. CHABER: NO, I DON'T HAVE ANOTHER COPY.
26 MR. OHLEMEYER: EXCUSE ME, YOUR HONOR.
27 THE COURT: YES.
28 MR. OHLEMEYER: I'D LIKE TO SEE IT.
JUDITH ANN OSSA, CSR NO. 2310

0054

1 THE COURT: YOU WANT TO SEE IT? SURE.
2 MS. CHABER: Q. THIS IS THE ARTICLE THAT WE'VE
3 MARKED AS 78 THAT YOU'RE FAMILIAR WITH, DOCTOR?
4 A. (EXAMINING) SUSTER, YES.
5 Q. AND, DOCTOR, I'LL DIRECT YOU -- YOU DON'T HAVE
6 GLASSES WITH YOU?
7 A. I DO.
8 Q. YOU DO. OKAY. SO IF YOU NEED TO READ ALONG,
9 YOU'LL BE ABLE TO DO THAT.
10 DOCTOR, ISN'T IT TRUE THAT THE FOLLOWING
11 STATEMENT WAS MADE BY SAUL SUSTER.
12 FIRST OF ALL, BEFORE I DO THAT, SAUL SUSTER WAS
13 AT THE MT. SINAI MEDICAL CENTER AND UNIVERSITY OF MIAMI
14 SCHOOL OF MEDICINE?
15 A. YES.
16 Q. AND CESAR MORAN IS FROM THE ARMED FORCES
17 INSTITUTE OF PATHOLOGY IN WASHINGTON?
18 A. I BELIEVE SO.
19 Q. AND IT'S TRUE, IS IT NOT, THAT THEY STATE THE
20 FOLLOWING AT PAGE 115:
21 "THE RENDERING OF A DIAGNOSIS OF PRIMARY SMALL
22 CELL CARCINOMA OF THE THYMUS MUST BE BASED ON THE
23 EXCLUSION OF A PRIMARY TUMOR ELSEWHERE"?
24 DO YOU AGREE THAT THAT IS WHAT THEY SAID?
25 A. NOT ONLY THAT, BUT I AGREE WITH THE STATEMENT.
26 Q. OKAY. AND WOULD YOU AGREE THAT THE NEXT SENTENCE
27 READS AS FOLLOWS:
28 "THIS CAN BE VERY DIFFICULT TO ESTABLISH IN THE
JUDITH ANN OSSA, CSR NO. 2310

0055

1 MAJORITY OF PATIENTS DURING LIFE, SINCE SMALL
2 CELL CARCINOMA OF THE LUNG IS KNOWN TO
3 METASTASIZE MASSIVELY TO THE MEDIASTINUM AT A
4 VERY EARLY STAGE WHEN THE PRIMARY IS NOT
5 DETECTABLE BY RADIOGRAPHIC MEANS"?
6 IS THAT A CORRECT READING OF THE NEXT STATEMENT?
7 A. THAT'S WHAT IT SAYS.
8 Q. AND YOU WOULD AGREE THAT IN THIS CASE, THE
9 SURGEONS ELECTED NOT TO DO WASHINGS AND BRUSHINGS,
10 CORRECT --
11 A. YES.
12 Q. -- IN MS. HENLEY'S CASE?
13 A. THEY DID.
14 Q. AND YOU WOULD AGREE THAT YOU'RE NOT QUARRELING
15 WITH THEIR COMPETENCE TO MAKE THAT DECISION AT THE TIME THAT
16 THEY RENDERED IT, ARE YOU?
17 A. IT'S A DECISION I WOULD DISAGREE WITH. BUT I

18 WOULD NOT SIT IN JUDGMENT OF THEIR REASONS FOR NOT DOING IT,
19 BECAUSE I HAVEN'T TALKED WITH THEM, AND I DON'T KNOW WHAT
20 THEIR THINKING WAS AT THE MOMENT.

21 BUT I WOULD REGARD THAT AS A CRITICAL MISTAKE
22 THAT MAKES IT IMPOSSIBLE NOW TO BE SURE WHERE THE CANCER
23 ORIGINATED FROM.

24 Q. YOU UNDERSTAND THAT THE SURGEON WHO PERFORMED
25 THAT SURGERY DOESN'T THINK IT'S IMPOSSIBLE TO DETERMINE THE
26 ORIGIN OF THE CANCER?

27 MR. OHLEMEYER: YOUR HONOR, I OBJECT. IT'S
28 ARGUMENTATIVE.

JUDITH ANN OSSA, CSR NO. 2310

0056

1 THE COURT: SUSTAINED.

2 MS. CHABER: Q. LET'S ASSUME, DOCTOR, THAT THE
3 SURGEON WHO PERFORMED THAT SURGERY CAME INTO COURT AND
4 TESTIFIED THAT THIS IS A SMALL CELL CANCER OF THE LUNG.

5 CAN YOU MAKE THAT ASSUMPTION?

6 A. I CAN ASSUME THAT HE SAID THAT.

7 Q. AND CAN YOU ASSUME FURTHER THAT THAT SURGEON WAS
8 COMFORTABLE WITH THAT DIAGNOSIS, BASED ON ALL OF THE
9 MATERIALS YOU HAVE EXAMINED?

10 A. NOT NECESSARILY. IF I WERE IN HIS SHOES, I WOULD
11 NOT BE COMFORTABLE AT ALL. I DON'T THINK THAT THE WEIGHT OF
12 EVIDENCE INDICATES THAT THE DIAGNOSIS OF LUNG CANCER WAS
13 CORRECT, LOOKING BACK ON IT.

14 I WANT TO EMPHASIZE THAT HERE WE HAVE THE BENEFIT
15 OF LOOKING AT THE TOTAL PICTURE, IN RETROSPECT, BUT I'M NOT
16 QUARRELING WITH PEOPLE WHO DIDN'T HAVE THE BENEFIT OF THAT
17 VIEW.

18 Q. DO YOU KNOW, SIR, WHETHER OR NOT THE SURGEON HAS
19 REVIEWED ALL THE MATERIALS THAT YOU'VE REVIEWED? YOU DON'T
20 KNOW THAT, DO YOU?

21 A. I'M TALKING ABOUT THE DIFFERENCE OF JUDGMENT AT
22 THE TIME THE DIAGNOSIS WAS MADE BACK IN JANUARY, I BELIEVE.

23 Q. AT THE TIME THAT THAT DIAGNOSIS WAS MADE, IS IT
24 FAIR TO SAY, DOCTOR, THAT THERE WASN'T ANYBODY IN THE COURSE
25 OF THIS THAT INDICATED A DIFFERENTIAL OR A CONSIDERATION
26 THAT THIS WAS A THYMIC ORIGIN CANCER?

27 A. THE SPECIFIC INFORMATION WAS NOT IN THE RECORDS
28 THAT I READ, SO I REALLY CAN'T SAY.

JUDITH ANN OSSA, CSR NO. 2310

0057

1 Q. AND, DOCTOR, YOU WOULD AGREE THAT SMALL CELL
2 CARCINOMAS OF THE LUNG ARE KNOWN TO METASTASIZE MASSIVELY TO
3 THE MEDIASTINUM?

4 A. WHICH DID NOT OCCUR IN THIS CASE.

5 BUT YES, I AGREE WITH THAT STATEMENT.

6 Q. DO YOU AGREE THAT SMALL CELL CARCINOMAS OF THE
7 LUNG CAN METASTASIZE TO THE MEDIASTINUM AND NOT HAVE A
8 LESION BEING SEEN IN THE BRONCHUS?

9 A. I DO. THAT'S EXACTLY WHY WE USE THOSE TECHNIQUES
10 THAT WE PREVIOUSLY TALKED ABOUT.

11 Q. DO YOU AGREE THAT YOU CANNOT RULE OUT MS.
12 HENLEY'S CANCER BEING A LUNG CANCER?

13 A. NO, NOT WITH 100 PERCENT CERTAINTY.

14 Q. AND, DOCTOR, I JUST WANT TO ASK YOU, IN LIGHT OF
15 THE TIME, JUST ONE OR TWO FINAL QUESTIONS.

16 DR. HENSLEY, DO YOU BELIEVE THAT CIGARETTE
17 SMOKING CAUSES ANY DISEASE?

18 A. WELL, I'M NOT AN EXPERT ON ALL OF THE POSSIBLE
19 DISEASES THAT HAVE BEEN RELATED TO CIGARETTE SMOKING. IF
20 YOU WISH TO CONFINE IT TO THE QUESTION OF CANCER, I HAVE TO

21 SAY THAT THERE IS STRONG STATISTICAL EVIDENCE TO CONSIDER
22 THE HYPOTHESIS THAT I REGARD AS YET UNPROVEN, THAT CIGARETTE
23 SMOKING MAY CAUSE CERTAIN CANCERS OF THE LUNG, BUT CERTAINLY
24 NOT ALL OF THEM.

25 AND I WANT TO EMPHASIZE THAT WE'RE TALKING HERE
26 NOT ABOUT HARD SCIENTIFIC CONCLUSIONS BUT ABOUT HYPOTHESES
27 THAT ARE INCOMPLETELY SUPPORTED BY THE FACTS AT PRESENT.

28 Q. FIRST OF ALL, YOU'VE NEVER WORKED ON ANY SURGEON
JUDITH ANN OSSA, CSR NO. 2310

0058

1 GENERAL COMMITTEES OR BEEN INVOLVED IN WRITING ANY OF THE
2 SURGEON GENERAL REPORTS, HAVE YOU?

3 A. NO, MA'AM.

4 Q. HAVE YOU HAVE READ THE SURGEON GENERAL REPORTS ON
5 THE HEALTH CONSEQUENCES OF SMOKING?

6 MR. OHLEMEYER: YOUR HONOR, I DON'T WANT TO
7 INTERRUPT, BUT THIS IS BEYOND THE SCOPE OF THE DIRECT.

8 MS. CHABER: IT GOES TO CREDIBILITY ISSUES AND
9 IT GOES TO BIAS.

10 THE COURT: LET ME JUST HAVE A VERY, VERY BRIEF
11 SIDEBAR WITH YOU.

12 (COURT AND COUNSEL CONFER OUTSIDE
13 THE PRESENCE OF THE JURY)

14 THE COURT: FOR THE RECORD, DO YOU WANT TO
15 WITHDRAW AND REPHRASE THAT QUESTION?

16 MS. CHABER: SURE.

17 Q. DR. HENSLEY, MS. HENLEY HAD A SMOKING HISTORY,
18 DID SHE NOT?

19 A. SHE DID.

20 Q. AND SHE HAD A SMOKING HISTORY OF SOMEWHERE
21 BETWEEN 90 AND 120 PACK YEARS?

22 A. I DON'T REMEMBER, BUT I BELIEVE YOU.

23 Q. AND DOCTOR, LET ME TRY THIS A LITTLE MORE
24 DIRECTLY.

25 DO YOU BELIEVE THAT CIGARETTE SMOKING CAUSES LUNG
26 CANCER?

27 MR. OHLEMEYER: ASKED AND ANSWERED, YOUR HONOR.

28 MS. CHABER: HE NEVER ANSWERED IT.

JUDITH ANN OSSA, CSR NO. 2310

0059

1 THE COURT: I WILL ALLOW IT.

2 THE WITNESS: I DON'T THINK THAT THE SCIENTIFIC
3 STANDARDS HAVE BEEN MET THAT WOULD PERMIT A SCIENTIFIC
4 ANSWER TO YOUR QUESTION.

5 I WANT TO EMPHASIZE THAT I AM IN NO WAY
6 DISAGREEING WITH THE SURGEON GENERAL'S REPORT FROM A PUBLIC
7 HEALTH STANDPOINT. I BELIEVE IT EXPRESSES WELL-FOUNDED
8 CONVICTIONS OF RESPECTABLE SCIENTISTS.

9 I DON'T BELIEVE THEY MET THE STANDARDS OF
10 SCIENTIFIC PROOF, BUT I CERTAINLY THINK THAT CIGARETTE
11 SMOKING IS AN IMPORTANT RISK FACTOR IN THE PRODUCTION OF
12 CANCERS IN SOME CANCERS OF THE LUNG. NOBODY WOULD DISAGREE
13 WITH THAT.

14 MS. CHABER: Q. DR. HENSLEY, SEE IF YOU CAN
15 ANSWER THIS YES OR NO, AND THEN YOU CAN EXPLAIN AS MUCH AS
16 YOU WANT TO: DO YOU BELIEVE THAT CIGARETTE SMOKING CAUSES
17 LUNG CANCER?

18 MR. OHLEMEYER: ASKED AND ANSWERED.

19 THE COURT: SUSTAINED.

20 MS. CHABER: Q. DO YOU BELIEVE CIGARETTE
21 SMOKING CAUSES EMPHYSEMA?

22 A. I THINK THE EVIDENCE FOR THAT IS VERY POOR.

23 Q. DO YOU THINK THAT CIGARETTE SMOKING CAUSES

24 CHRONIC BRONCHITIS?
25 A. IT'S A RISK FACTOR IN THE DEVELOPMENT OF
26 BRONCHITIS. IT'S CERTAINLY NOT THE CAUSE OF CHRONIC
27 BRONCHITIS.
28 Q. I USED THE WORD "CAUSE" THE SAME WAY THE SURGEON
JUDITH ANN OSSA, CSR NO. 2310

0060

1 GENERAL USED IT IN THE 1979 REPORT, AS A SIGNIFICANT
2 EFFECTUAL RELATIONSHIP BETWEEN AN AGENT AND AN ASSOCIATED
3 DISORDER OR DISEASE.
4 DO YOU BELIEVE, DOCTOR, THAT CIGARETTE SMOKING
5 CAUSES EMPHYSEMA?
6 A. THIS IS NOT SCIENTIFICALLY LOGICAL. WHAT YOU
7 JUST ASKED ME TO DO IS ABANDON SCIENTIFIC LOGIC AND AGREE
8 WITH THE PRINCIPLE OF GUILT BY ASSOCIATION.
9 THOSE STATEMENTS ARE BASED ON STATISTICAL
10 STUDIES. THE BEST THE STATISTICS CAN DO IS TO HELP US TO
11 FORMULATE SCIENTIFIC HYPOTHESES, WHICH NEEDS TESTING BEFORE
12 SCIENTIFIC EVIDENCE IS BROUGHT FORWARD.
13 Q. DOCTOR --
14 A. SO I CANNOT POSSIBLY ANSWER IT IN THOSE TERMS.
15 Q. DR. HENSLEY, YOU'RE AWARE THAT THE SURGEON
16 GENERAL OF THE UNITED STATES, THE WORLD HEALTH ORGANIZATION,
17 THE INTERNATIONAL ASSOCIATION OF RESEARCH OF CANCER, HAVE
18 ALL STATED THAT CIGARETTE SMOKING CAUSES THE DEFINITION THAT
19 I JUST GAVE FOR LUNG CANCER?
20 A. IN 1964, IN THE SURGEON GENERAL'S REPORT, HE SAID
21 THAT THEY WOULD LIKE TO PRESENT EVIDENCE THAT WOULD LEAD TO
22 THE CONVICTION OF CAUSATION WITH THE CLASSICAL EXACTNESS OF
23 ARISTOTLE.
24 WHEN THEY CONCLUDED THE RECORD, THEY ABANDONED
25 THOSE PRINCIPLES OF LOGIC AND SCIENCE AND SAID THAT THEY
26 CAME TO A CONVICTION ABOUT CAUSATION BASED ON THE
27 INFORMATION THAT WAS CONTAINED IN THAT REPORT.
28 I HEARTILY APPLAUD THEM FOR THAT, AND I AGREE
JUDITH ANN OSSA, CSR NO. 2310

0061

1 WITH THEIR EFFORT, AND I THINK IT WAS AN IMPORTANT
2 CONTRIBUTION TO PUBLIC HEALTH, BUT I CANNOT ACCEPT IT AS A
3 SCIENTIFICALLY PROVEN HYPOTHESIS.
4 BUT DON'T MISTAKE MY MEANING. I RESPECT THEIR
5 WORK.
6 Q. DR. HENSLEY, 34 YEARS LATER, ALL OF THE
7 ORGANIZATIONS, THE SURGEON GENERAL, THE WORLD HEALTH
8 ORGANIZATION, THE INTERNATIONAL ASSOCIATION FOR RESEARCH OF
9 CANCER, THEY HAVE ALL CONCLUDED A CAUSE-AND-EFFECT
10 RELATIONSHIP BETWEEN LUNG CANCER AND CIGARETTE SMOKING --
11 A. COUNSELOR, THIS IS --
12 MR. OHLEMEYER: I'M SORRY. I OBJECT, YOUR
13 HONOR.
14 MS. CHABER: I WASN'T FINISHED WITH MY SENTENCE.
15 MR. OHLEMEYER: IT IS ARGUMENT, NOT A QUESTION.
16 THE COURT: THERE ISN'T A QUESTION YET.
17 THE WITNESS: I'M SORRY.
18 THE COURT: IF THERE IS A QUESTION AND IF YOU
19 HAVE AN OBJECTION, MAKE IT, BUT WE HAVEN'T HEARD A QUESTION.
20 MS. CHABER: Q. IS THAT SOMETHING THAT YOU
21 DISAGREE WITH TODAY, IN 1999?
22 MR. OHLEMEYER: OBJECTION. IT'S ARGUMENTATIVE,
23 AND IT'S BEEN ASKED AND ANSWERED --
24 THE COURT: SUSTAINED.
25 MR. OHLEMEYER: -- FOUR TIMES.
26 THE COURT: SUSTAINED.

27 MS. CHABER: I HAVE NOTHING FURTHER.
28 THE COURT: ANYTHING FURTHER?
JUDITH ANN OSSA, CSR NO. 2310

0062

1 MR. OHLEMEYER: I JUST HAVE TWO OR THREE.
2 REDIRECT EXAMINATION
3 BY MR. OHLEMEYER: Q. DR. HENSLEY, WHEN YOU
4 DIAGNOSE CANCER, DO YOU DO IT BASED ON PROBABILITIES OR
5 BASED ON ANATOMY?
6 A. ANATOMY AND PATHOLOGY.
7 Q. AND ARE PROBABILITIES MORE OF LESS USEFUL TO YOU
8 IN YOUR WORK IN DIAGNOSING CANCER THAN ANATOMICAL
9 INFORMATION?
10 A. STATISTICAL PROBABILITIES ARE PRACTICALLY NO
11 VALUE IN MY WORK.
12 Q. DOES THE ANATOMICAL EVIDENCE IN THIS CASE SUGGEST
13 THAT IT'S MORE OR LESS LIKELY THAT MS. HENLEY'S CANCER
14 STARTED IN HER LUNG?
15 A. IT'S LESS LIKELY. THERE'S NO EVIDENCE THAT THE
16 CANCER STARTED IN THE LUNG, AND THERE'S NO EVIDENCE IN THE
17 MEDICAL RECORD OR THE X-RAYS THAT IT EVER INVOLVED THE LUNG
18 AT ALL.
19 Q. WHAT ABOUT THE LYMPH NODES?
20 A. THERE'S NO EVIDENCE THAT THE LYMPH NODES ARE
21 INVOLVED, FROM A PATHOLOGICAL STANDPOINT.
22 Q. WHY WOULD THAT SORT INVOLVEMENT BE IMPORTANT IF
23 YOU WERE TRYING TO DETERMINE WHETHER THE CANCER STARTED IN
24 THE LUNG?
25 A. WELL, SMALL CELL ANAPLASTIC CARCINOMAS STARTING
26 IN THE LUNG VIRTUALLY ALWAYS METASTASIZE MASSIVELY TO THE
27 LYMPH NODES, WHICH DID NOT OCCUR IN THIS CASE.
28 THERE IS A SINGLE MASS, AND IT WASN'T SITUATED IN

JUDITH ANN OSSA, CSR NO. 2310

0063

1 THE AREA WHERE SMALL CELL CANCER USUALLY METASTASIZES TO.
2 MR. OHLEMEYER: THANK YOU, DOCTOR. THAT'S ALL I
3 HAVE.
4 THE COURT: ANYTHING FURTHER FOR THE DOCTOR?
5 MS. CHABER: NO, YOUR HONOR.
6 THE COURT: MAY THE DOCTOR BE EXCUSED?
7 MS. CHABER: YES.
8 MR. OHLEMEYER: YES. THANK YOU, DOCTOR.
9 THE COURT: OKAY. DOCTOR, YOU ARE EXCUSED.
10 (WITNESS EXCUSED)
11 THE COURT: AND JURORS, LET'S KIND OF COMPROMISE
12 ON LUNCH AND LET'S TAKE AN HOUR AND 20 MINUTES.
13 JUROR NO. 3: I JUST WANT TO SAY THAT I HAVE A
14 VERY IMPORTANT MATTER THAT I NEED TO TAKE CARE OF AT
15 LUNCHTIME.
16 THE COURT: WHAT DO YOU WANT TO TAKE FOR LUNCH?
17 IT'S 12:25. WHEN DO YOU WANT TO COME BACK?
18 JUROR NO. 3: AN HOUR AND A HALF.
19 THE COURT: WE'LL COME BACK AT 2:00 O'CLOCK.
20 PLEASE CONTINUE TO FOLLOW THE ADMONITION OVER THE
21 LUNCH HOUR AND HAVE A GOOD LUNCH. WE'LL SEE YOU AT 2:00
22 O'CLOCK.
23 (LUNCH RECESS TAKEN AT 12:25 P.M.)

24 *****
25
26
27
28

JUDITH ANN OSSA, CSR NO. 2310